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 Prostate cancer is the second leading cause of cancer death in American 
men, yet despite the prevalence of this disease, there is a distinct lack of 
prognostic biomarkers for estimating the likelihood of prostate cancer 
aggressiveness.  The loss of cell-cell adhesion is frequently associated with the 
progression of prostate cancer to a metastatic state. While both adherens 
junctions and desmosomes are involved in establishing and maintaining this 
adhesion, previous studies of cell-cell adhesion in prostate cancer have focused 
solely on the role of adherens junctions, leaving the role of desmosomal 
adhesion unexplored. The goals of this thesis were to perform a functional 
analysis of the role and regulation of adherens junctions and desmosomes in 
aggressive prostate cancer, and to examine the efficacy of classical and 
desmosomal cadherins as prognostic biomarkers of aggressive prostate cancer. 
 I began this study by characterizing the expression profile of desmosomal 
cadherins in normal human prostate and metastatic prostate cancer cell lines. 
This study revealed that DSG2, DSC2, and DSG4 were consistently expressed 
 at a high level in the luminal cells of the prostate. Further, analysis of metastatic 
prostate cancer cell lines showed that the expression of DSG2 is present in most 
cell lines examined, while the expression of DSG4 is absent. 
 Following this characterization, I examined the role of E-cadherin and 
DSG2 in metastatic prostate cancer cell lines. Interestingly, the loss of E-
cadherin resulted in the inhibition of extensive primary and metastatic tumor 
formation, suggesting that E-cadherin may have a role in promoting the 
progression of prostate cancer in addition to its well-established role as a tumor 
suppressor. Additionally, the loss of E-cadherin based adherens junctions was 
not associated with the reciprocal loss of DSG2 based desmosomes, challenging 
the common belief that the formation of adherens junctions is a prerequisite for 
the formation of desmosomes.  
 I then examined the regulatory effects of PI3K/AKT signaling on E-
cadherin and DSG2 expression in metastatic prostate cancer cell lines. The 
expression of activated AKT was found to be associated with the inhibition of E-
cadherin expression, while the expression of DSG2 was relatively unperturbed in 
the presence of activated AKT expression. These results suggest that aberrantly 
activated PI3K/AKT signaling in prostate cancer may result in the loss of E-
cadherin expression, and that the loss of E-cadherin and DSG2 expression in 
prostate cancer may be regulated by separate pathways.  
 Finally, I examined the expression of E-cadherin and DSG2 in a large 
cohort of patients with prostate cancer to determine whether these cadherins 
were associated with prostate cancer aggressiveness. Interestingly, the loss of 
 these cadherins was found to be significantly associated with biochemical 
recurrence demonstrating their potential utility as prognostic markers of 
aggressive prostate cancer. 
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List of Abbreviations: 
 
 In general, human genes and RNA are written in italicized capital letters, 
while human proteins are written in non-italicized capital letters (e.g. DSG2 refers 
to the human gene or RNA while DSG2 refers to the human protein). Mouse 
genes and RNA are italicized with only the first letter capitalized, while murine 
proteins are non-italicized with only the first letter capitalized (e.g. Dsg2 refers to 
the murine gene or RNA while Dsg2 refers to the murine protein). 
 
AKT — v-akt murine thymoma viral oncogene homolog 1 
Arp2/3 — Actin related protein 2/3 complex  
ARVC — Arrhythmogenic right ventricular cardiomyopathy 
BPH-1 — Benign prostatic hyperplasia 1 
BSA — Bovine Serum Albumin 
Cdc42 — Cell division cycle 42 (GTP binding protein, 25kDa) 
ChIP — Chromatin immunoprecipitation   
CK8/18 — Cytokeratin 8/18 
C-RAF — v-raf-1 murine leukemia viral oncogene homolog 1  
DAPI — 4’,6-diamidino-2-phenylindole 
DP — Desmoplakin  
DSC — Desmocollin 
DSG — Desmoglein 
EcadKD — E-cadherin knock down 
EGF — Epidermal growth factor 
EGFR — Epidermal growth factor receptor 
EMT — Epithelial-mesenchymal transition 
ER — Estrogen Receptor 
ErbB2 — v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian); also known as 
HER2 
FBS — Fetal Bovine Serum 
FFPE — Formalin-fixed paraffin-embedded   
FGF — Fibroblast growth factor 
FGFR1 — Fibroblast growth factor receptor 1 
Foxo3a — Forkhead Box O3a 
GDP — Guanosine Diphosphate 
GEF — Guanine Nucleotide Exchange Factor 
GFP — Green Fluorescent Protein 
Gli — GLI family zinc finger  
GRB2 — Growth factor receptor-bound protein 2 
GSK3β — Glycogen synthase kinase 3 beta 
GTP — Guanosine 5’ Triphosphate 
HA-tag — Hemagglutinin tag 
H&E — Hematoxylin and eoisin  
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HER2 — v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,      
neuro/glioblastoma derived oncogene homolog (avian); also known as 
ERBB2 
HF — Hair follicle 
HGF/SF — Hepatocyte growth factor/scatter factor 
HGMA2 — High mobility group A2 
Hh — Hedgehog  
IGF2 — Insulin-like growth factor 2 
IGF-IR — Insulin-like Growth Factor I Receptor 
INPP4B — Inositol polyphosphate-4-phosphatase, type II, 105kDa 
IQGAP1 — IQ motif containing GTPase activating protein 1 
IRS — Inner root sheath 
K14 — Keratin 14 
LOH — Loss of Heterozygosity 
MAH — Myristoylated AKT HA-tagged 
MAPK — Mitogen activated protein kinase 
MDCK — Madin Darby Canine Kidney 
MET — Mesenchymal-epithelial transition  
MPAKT — Murine prostate restricted Akt kinase activaty transgenic 
mTOR — Mammalian target of rapamycin 
myrAkt — Myristoylated AKT 
NICD — Notch intracellular domain 
N-WASP— Neuronal Wiskott Aldrich sydrome protein 
ORS — Outer root sheath 
pAKT — Phosphorylated AKT 
PBS — Phosphate Buffered Saline 
PCR — Polymerase chain reaction 
PDGF — Platelet-derived growth factor 
PDK1 — Phosphatidylinositol-dependent kinase 1 
PIK3CA — Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide 
PG — Plakoglobin 
PH domain — Pleckstrin homology domain 
PHLLP — PH domain and leucine rich repeat protein phosphatase 
PIN — Prostatic Intraepithelial Neoplasia 
PI3K — Phosphatidylinositol 3-Kinase 
PIP — Phosphatidylinositol (3) phosphate; also known as PI(3)P  
PIP2 — Phosphatidylinositol (3, 4) biphosphate; also known as PI(3,4)P2 or   
  Phosphatidylinositol (4, 5) biphosphate; also known as PI(4,5)P2 
PIP3 — Phosphatidylinositol (3, 4, 5) triphosphate; also known as PI(3, 4, 5)P3 
PKP — Plakophilin 
PPKS — Striate palmoplantar keratoderma  
PR — Progesterone Receptor  
PSA — Prostate Specific Antigen 
PTEN — Phosphatase and tensin homolog  
qRT-PCR — quantitative real-time polymerase chain reaction 
  vi
Rac1 — Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP  
binding protein Rac1) 
Ras — Rat sarcoma viral oncogene homolog 
Rho — Rhodopsin 
RNAi — RNA interference 
RTK — Receptor Tyrosine Kinase     
RT-PCR — Reverse Transcription Polymerase Chain Reaction  
SDS — Sodium dodecyl sulfate 
SDS-PAGE— Sodium dodecyl sulfate polyacrylamide gel electrophoresis   
SH2 — Src Homology 2 
shRNAmir — microRNA adapted short hairpin RNA 
siRNA — small interfering RNA 
SOS — Son of sevenless 
Src — v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 
TCF — T cell factor 
TGFβ — Transforming growth factor β 
Tiam1 — T-cell lymphoma invasion and metastasis 1 
TMA —Tissue Microarray 
TNM —Tumor, Nodes, Metastases 
VEGF — Vascular endothelial growth factor 
VEGFR-3 — Vascular endothelial growth factor receptor 3  
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1.  Anchoring Junctions: Adherens Junctions and Desmosomes 
 Multicellular organisms rely on cell-cell adhesion for the development, 
differentiation, and maintenance of their tissues. A variety of cell-cell junctions 
serve this purpose, with functions ranging from establishing a physical 
connection between cells to establishing a channel of communication between 
cells. Cell-cell anchoring junctions are an example of a junction that functions to 
establish a physical connection between cells by anchoring cells via the 
cytoskeleton. Cell-cell anchoring junctions are comprised of two subtypes that 
differ in the cytoskeletal filaments to which they attach. The first subtype is the 
adherens junction which forms a physical connection to actin microfilaments. The 
second subtype is the desmosome which forms a physical connection to 
intermediate filaments, thereby conferring an additional degree of strength to 
tissues that undergo a high level of mechanical stress. These junctions are 
interdependent with respect to their assembly and regulation, and the 
significance of this interdependence is evidenced by the multitude of both 
developmental aberrations and human diseases resulting from their 
disregulation.   
 The core of the adherens junction is comprised of members of two protein 
families—cadherins and catenins. The cadherin family is represented by the 
“classical” cadherins, so named because they were the first type of cadherin 
within the cadherin superfamily to be discovered. The first three classical 
cadherins discovered were named according to the main cell type in which they 




tissues, N-cadherin is the predominant cadherin in neurons, and P-cadherin is 
the predominant cadherin in the placenta (Nagafuchi et al., 1987; Nose et al., 
1987; Hatta et al., 1988).  The catenin family is represented by members of the 
armadillo superfamily including p120-catenin, β-catenin, and plakoglobin (γ-
catenin); as well as the structurally unrelated α-catenin (Meng and Takeichi, 
2009). The assembly of adherens junctions is initiated via a calcium-dependent, 
homophilic interaction of the extracellular regions of cadherins in the extracellular 
space between opposing cells. This interaction then leads to the binding of the 
cadherin cytoplasmic tails to p120-catenin as well as β-catenin or plakoglobin, 
followed by the binding of β-catenin to α-catenin (Stepniak et al., 2009). This core 
complex is then linked to the actin cytoskeleton via interactions between α-
catenin and actin binding proteins such as eplin, formin, and vinculin (Fig. 1) 
(Abe and Takeichi, 2008; Kobielak et al., 2004; Watabe-Uchida et al., 1998).   
 





 Desmosomes are comprised of members from three protein families—the 
cadherin family, the armadillo family, and the plakin family. In the desmosome, 
the cadherin family is represented by “non-classical” cadherins which include 
desmogleins (DSG 1-4) and desmocollins (DSC1-3), while the armadillo family is 
represented by plakoglobin (PG) and plakophilins (PKP 1-4), and the plakin 
family is represented by desmoplakin (DP) (Getsios et al., 2004). Desmogleins 
and desmocollins play a dual role in the formation of desmosomes. In the 
extracellular space, desmogleins and desmocollins on opposing cells interact in a 
heterophilic calcium-dependent manner via their cadherin repeat domains. 
Intracellularly, the cadherins bind to plakoglobin and plakophilin, which in turn 
bind to desmoplakin. Desmoplakin then binds to intermediate filaments, thereby 
securing the entire structure to the cytoskeleton (Fig. 2) (Tselepis et al., 1998; 
Delva et al., 2009). Unlike classical cadherins which preferentially bind to β-
catenin, but are also able to substitute plakoglobin for β-catenin in cases where 
β-catenin is unavailable, desmosomal cadherins cannot substitute β-catenin for 
plakoglobin and the affinity of plakoglobin for desmosomal cadherins is much 





Figure 2: The desmosome (Adapted from Fuchs and Raghavan, 2002) 
 
2. Assembly of Adherens Junctions 
 Cell-cell adhesion is initiated when cells contact one another through the 
extension of either lamellipodia or filopodia. These projections are formed when 
actin microfilaments are organized perpendicular to the leading edge of the cell in 
either a web-like branched actin network or in linear bundles thereby forming 
lamellipodia or filopodia, respectively (Pollard and Borisy, 2003; Vasioukhin et al., 
2000).  E-cadherin has been shown to coassemble with β-catenin and α-catenin, 
in a complex referred to as a “puncta”, at sites of cell-cell contact (Adams et. al, 
1996). In vitro analysis of GFP-tagged E-cadherin in Madin Darby Canine Kidney 
(MDCK) epithelial cells has shown that the contact of lamellipodia on opposing 
cells initiates the spontaneous clustering and immobilization of puncta at the site 
of cell-cell contact, followed by an interaction between the cadherin-catenin 
complex and actin microfilaments that have branched from the cortical actin 




plaques at either end of the developing contact (Adams et al., 1998). With the 
maturation of this intercellular adhesion, cortical actin is replaced by 
circumferential actin bundles attached to the interface of adhering cells, thereby 
forming the belt-like band of adherens junctions typical of a polarized epithelial 
cell (Yonemura et al., 1995). In vitro analysis of freshly isolated primary mouse 
keratinocytes has shown that opposing cells extend filopodia, and upon contact 
with a neighboring cell, the filopodia slide along each other until they finally 
project into the membrane of the neighboring cell, a process which forces the 
membranes of opposing cells together. Puncta then form at the tips of the 
embedded filopodia, resulting in a double row of puncta referred to as an 
“adhesion zipper”, which serves to stabilize the interaction site of the neighboring 
cells. As a result of this stabilization, the opposing surfaces of the neighboring 
cells are further drawn together. These filopodial projectiles were also identified 
in epidermal cells of mouse skin, suggesting that this process of intercellular 
adhesion exists in vivo as well as in vitro (Vasioukhin et al., 2000).  
  
3. Assembly of Desmosomes 
 The formation of adherens junctions has been shown to precede that of 
desmosomes. In the in vitro analysis of primary mouse keratinocytes conducted 
by Vasioukhin et al., desmosomes were first detected at the flanking ends of the 
adhesion zipper. As filopodia contain actin microfilaments, and not keratin 
intermediate filaments, the formation of desmosomes in the early stages of 




of desmosomes may serve to stabilize the newly formed intercellular contact site. 
 The details of desmosome assembly are not as fully understood, though 
key studies have provided critical insight into the possible mechanism. Calcium 
switch experiments, in which cells grown in low calcium conditions (less than 
0.1mM) that do not favor cadherin based adhesion are switched to high calcium 
conditions (greater than 0.1mM) which allow for cadherin based adhesion, have 
shown that all desmosomal proteins are continuously expressed in a low calcium 
state (Duden et al., 1988). Under these low calcium conditions, desmosomal 
proteins transiently assemble into “half-desmosomes”— plaques that contain 
desmosomal proteins and localize to the cell membrane but do not attach to 
desmosomal plaques on an opposing cell surface. These half-desmosomes are 
continuously recycled via endocytosis in the absence of cell-cell contact and 
accumulate in cytoplasmic endocytic vesicles (Demlehner et al., 1995). Further in 
vitro analysis of GFP-tagged DP in the human epidermoid carcinoma A431 cell 
line has shown that cell-cell contact initiates the de novo appearance of punctate 
fluorescence at the contact site, followed by the colocatization of DP and PKP2 
into cytoplasmic particles, and the rapid translocation of these particles to the 
maturing contact in an actin microfilament dependent manner (Godsel et al., 
2005). The link between the assembly of adherens junctions and that of 
desmosomes is thought to lie with the desmosomal representatives of the 
armadillo family, plakoglobin and plakophilin. In vitro analysis of A431D — a 
derivative of the A431 cell line that expresses all desmosomal proteins except 




desmosomes are only able to form in the presence of a classic cadherin, and 
when sufficient levels of PG are expressed to accommodate association with 
both desmosomal and classic cadherins (Lewis et al., 1997). Further analysis of 
A431D cells has shown that the expression of PKP1 and a classic cadherin also 
results in the assembly of desmosomes at the cell-cell border (Wahl III, 2005). 
Taken together these studies suggest that the formation of adherens junctions 
triggers the accumulation of desmosomal proteins at the cell border and that this 
process may be regulated by PG and PKP.  
  
4. Regulation of Anchoring Junction Assembly 
 The assembly of anchoring junctions is regulated in part by the Rho family 
of small GTPases. These small GTPases serve as molecular switches within the 
cell, and are themselves subject to tight temporal and spatial regulation. Small 
GTPases are present in either a GDP-bound inactive or GTP-bound active state, 
and the exchange of GDP for GTP is mediated by guanine nucleotide exchange 
factors (GEFs) (Watanabe et al., 2009). Upon initiation of E-cadherin based cell-
cell adhesion, Rac1 and Cdc42 — members of the Rho family of small GTPases 
— translocate from the cytosol to the sites of cell-cell junctions and become 
active (Jou and Nelson, 1998; Nakagawa et al., 2001; Kim et al., 2000). This 
accumulation of Rac1 and Cdc42 may be mediated by phosphatidlyinositol 3-
kinase (PI3K) which is thought to function upstream of Rac1 as inhibiting the 
activity of PI3K has been shown to inhibit the activation of Rac1 (Kotani et al., 




recruited to sites of E-cadherin mediated cell-cell adhesion, and that PI3K is 
activated as a result of this adhesion (Perez et al., 2008; Pece et al., 1999). 
Through the use of in vitro calcium-switch experiments, Pece et al. demonstrated 
that the formation of adherens junctions leads to the activation of AKT, a 
downstream effector of PI3K. This activation of AKT was dramatically reduced in 
the presence of wortmannin, an inhibitor of PI3K. When E-cadherin mediated 
adhesion was interrupted in high calcium conditions using antibodies that target 
E-cadherin and block its capacity for homophilic interaction, the activation of AKT 
was also dramatically reduced. The physical association of PI3K and E-cadherin 
via coimmunoprecipitation was also demonstrated. These results suggest that 
PI3K interacts directly with E-cadherin at sites of cell-cell adhesion, and that this 
interaction leads to the activation of PI3K which may then lead to the 
accumulation of small GTPases at sites of cell-cell adhesion. 
 Much like Rac1 and Cdc42, GEFs, such as Tiam1, also accumulate at 
sites of adherens junctions (Hordijk et al., 1997). This accumulation may be 
mediated by the interaction of the Tiam1 PDZ domain with the PDZ consensus 
sequence found in β-catenin, which could account for the activation of Rac1 and 
Cdc42 at adherens junctions (Songyang et al., 1997; Michiels et al., 1995; 
Dobrosotskaya et al., 2000). Additionally, Tiam1 contains a PH domain which 
allows it to bind to phosphatidlyinositol lipids,  products of PI3K, thereby allowing 
it to dock at sites of PI3K activity and serving as a means by which Tiam1 is 
recruited to sites of cell-cell adhesion in a PI3K dependent manner (Rameh et al., 




 Once active at sites of cell-cell adhesion, small GTPases play a regulatory 
role in the formation of adherens junctions by enhancing the formation of these 
junctions through inhibition of a negative regulator of E-cadherin based adhesion 
and through modifications of the actin cytoskeleton that serve to reinforce 
cadherin-mediated adhesion. Overexpression of constitutively active mutant of 
Rac1 has been shown to induce the accumulation of E-cadherin, β-catenin, and 
actin filaments at sites of cell-cell contact, while the overexpression of a dominant 
negative mutant of Rac1 has been shown to reduce this accumulation (Takaishi 
et al., 1997). Rac1 and Cdc42 have also been shown to bind to and inactivate 
IQGAP1, a negative regulator of adherens junction formation that interacts with 
β-catenin and dissociates α-catenin from β-catenin (Kuroda et al., 1998; Fukata 
et al., 1999). Additionally, Cdc42 and PIP2 have been shown to interact with N-
WASP thereby enhancing the ability of N-WASP to interact with the Arp2/3 
complex. The Arp2/3 complex is required for the nucleation of actin microfilament 
assembly, and by interacting with N-WASP in a Cdc42 dependent manner, the 
Arp2/3 complex is able to initiate this actin microfilament assembly at sites of 
cell-cell adhesion (Rohatgi et al., 1999; Rohatgi et al., 2000). 
 
5. Adherens Junctions and Desmosomes in Development 
 The formation of anchoring junctions is crucial in embryonic development.  
In the preimplantation embryo, E-cadherin is initially provided maternally, and at 
the 8-cell stage of embryonic development, E-cadherin is critical for compaction 




adherent to highly polarized and flattened with a significant increase in adherens 
junctions along the maximized contact surface between cells (Ohsugi et al., 
1996). Subsequent asymmetric cell division gives rise to a 16-cell morula that 
contains inner daughter cells surrounded by an outer cell layer which 
preferentially contributes to the trophectoderm. E-cadherin expression by the 
embryo at the morula stage is critical for the formation of the trophectoderm, as 
mutant mice that lack E-cadherin expression die at E4 due to defects in 
trophectoderm formation (Fleming et al., 1987; de Vries et al., 2004; Larue et al., 
1994).    
 Much like de novo anchoring junction formation between the cells of adult 
tissues, the formation of adherens junctions precedes the formation of 
desmosomes in the preimplantation embryo. Desmosomes initially form in the 
mature trophectoderm at the 32-cell stage. While the expression of PG can be 
detected as early as the 8-cell stage, the expression of most desmosomal 
cadherins is not detected until the 32-cell stage (Jackson et al., 1980; Fleming et 
al., 1991). The importance of desmosomes in early development is underscored 
by the phenotypes of mutant mice lacking desmosomal protein expression. 
Mutant mice that lack the expression of DP are able to form a trophectoderm, 
however these mice die after implantation at E6.5. The DP null embryos show a 
dramatic reduction in cell proliferation and fragility upon mechanical dissection, 
suggesting that the mutant embryos are unable to handle the increased 
proliferation and tissue reorganization that occurs between E5.0 and E7.0 




die at E3.5 or at the time of implantation, respectively. Interestingly, in both cases 
the formation of trophectoderm appears normal, indicating a possible role for 
desmosomal cadherins beyond that of desmosomal architecture (Den et al., 
2006; Eshkind et al., 2002).   
 
6. EMT and Development 
 Epithelial-mesenchymal transition (EMT) is essential in early embryonic 
developmental processes such as gastrulation. In EMT, cells lose epithelial 
characteristics such as apical-basal polarity and cell-cell adhesion, and acquire 
mesenchymal characteristics such as motility. Prior to implantation, the mouse 
embryo is effectively a ball of cells consisting of an inner cell mass and the 
trophectoderm. Following implantation, the embryo undergoes dramatic changes 
in size and shape that result in the formation of a trophoblast, hypoblast, 
epithelialized epiblast, and amniotic cavity (Tam and Behringer, 1997). During 
gastrulation, the cells of the epiblast (embryonic ectoderm) undergo complex 
morphogenetic rearrangements that result in the formation of the three primary 
germ layers, basic body plan, and primitive gut (Tam et al., 1987).   
 Gastrulation is initiated by the formation of the primitive streak. Prior to the 
formation of the primitive streak, cells of the epiblast are tightly packed and 
express E-cadherin (Damjamov et al., 1986). The primitive streak is formed when 
cells of the epiblast undergo ingression and de-epithelialization thereby losing 
contact with neighboring cells (Bellairs et al., 1986; Hashimoto and Nakatsuji, 




endodermal cells to migrate along the streak, and is concomitant with the loss of 
E-cadherin expression (Burdsal et al., 1993; Damjanov et al., 1986). FGF 
signaling plays a critical role in gastrulation as mouse embryos lacking the 
expression of FGF Receptor 1 (Fgfr1) die before or during gastrulation (Deng et 
al., 1994). In vitro analysis of Fgfr1 -/- embryonic tissue explants from the primitive 
streak shows that in the absence of Fgfr1 expression cells have defects in 
migration and aberrantly accumulate beneath the primitive streak while 
maintaining E-cadherin expression (Ciruna et al., 2001).  Ciruna and colleagues 
went on to show that while Snail was expressed in the early primitive streak, 
there was a subsequent loss of Snail expression in the late primitive streak of 
Fgfr1 -/- mutant explants, suggesting that the expression of Fgfr1 is required for 
the maintenance of Snail expression. Snail is a zinc finger transcription factor 
that binds to E-boxes in the promoters of target genes and acts as a 
transcriptional repressor (Nieto, 2002). Snail has been shown to be a direct 
repressor of E-cadherin expression (Cano et al., 2000). Mice that lack the 
expression of Snail die at E8.5 and show defects in gastrulation and mesoderm 
formation. These mutant mice form an abnormal mesoderm layer that expresses 
mesodermal markers but retains epithelial features such as adherens junctions 
due to maintained E-cadherin expression (Carver et al., 2001). Thus the loss of 
E-cadherin expression via the EMT effector Snail is critical in early 






7. The PI3K/AKT Signaling Pathway  
 The PI3K/AKT signaling pathway is involved in a variety of cellular 
processes that regulate metabolism, protein synthesis, cell cycle, and cell 
survival. This pathway is activated when growth factors bind to their respective 
growth factor receptor tyrosine kinases (RTKs). A variety of growth factors have 
been shown to activate the PI3K/AKT signaling pathway including insulin, PDGF, 
EGF, and FGF (Burgering and Coffer, 1995). The ligand bound RTKs are then 
activated via autophosphorylation thereby creating a docking site that allows for 
the binding of adaptor proteins containing phosphotyrosine-binding domains such 
as SH2 domains. Class IA PI3Ks can either bind directly to the activated RTKs 
through their SH2 domain, or can bind via adaptor proteins, and in both cases 
this leads to activation of PI3K. Activated PI3K then phosphorylates inositol 
phospholipids at the 3 position to generate PI(3)P, PI(3,4)P2, or PI(3, 4, 5)P3 (PIP, 
PIP2, PIP3, respectively).  These phosphorylated inositol phospholipids then 
interact with the lipid binding domains of PI3K effector proteins leading to their 
activation. PI3K signaling can be inactivated at this point in the pathway by 
PTEN, a phosphatase that dephosphorylates PI(3, 4, 5)P3 converting it to 
PI(4,5)P2 (Maehama and Dixon, 1998). In the presence of PIP3, the 
serine/threonine kinase AKT serves as a major effector of PI3K signaling. The 
production of PIP3 recruits AKT and PDK1 to the membrane via their PH 
domains. At the membrane, AKT is activated when PDK1 phosphorylates AKT at 
threonine 308 (Thr308) in its activation loop while the rictor-mTOR complex 




then goes onto phosphorylate and inhibit a variety of proteins thereby promoting 
glucose metabolism, protein synthesis, cell proliferation, and survival (Fig. 3) 
(Vanhaesebroeck et al., 2010; Engelman et al., 2006; Cully et al., 2006; 
Sarbassov et al., 2005).  
 
Figure 3: PI3K/AKT signaling pathway (Adapted from Engelman et al., 2006) 
 
8. Prostate Cancer  
 Prostate cancer is the most frequently diagnosed cancer in American men 
as well as the second leading cause of cancer death. In 2009, The American 
Cancer Society estimates over 190,000 new cases of prostate cancer and over 
27,000 prostate cancer related deaths (American Cancer Society, 2009). 
Prostate cancer is generally diagnosed using a core needle biopsy, a method by 




prostate tissue. These core biopsies are submitted to a pathologist who then 
determines if cancer cells are present, and assigns a Gleason score in the event 
of cancer. This Gleason score is the result of the sum of two Gleason grades. 
The Gleason grades range from 1-5 with low Gleason grades corresponding to 
cancers that are well differentiated and high Gleason grades corresponding to 
cancers that are poorly differentiated. Well differentiated cancers are composed 
of glands which architecturally resemble normal prostate glands, while poorly 
differentiated cancers lack the shape and architecture of normal prostate glands. 
As prostate cancers are often comprised of areas with different grades, the 
Gleason score is obtained by adding the predominant grade (primary) and the 
second most predominant grade (secondary) when present. The Gleason score 
is divided into 3 categories: low (≤6), intermediate (7) and high (≥8), and has 
been shown to be a critical prognostic factor for patients with prostate cancer. 
Once prostate cancer has been graded it must then be staged to determine 
whether the cancer is confined to the prostate capsule, or whether it has spread 
to nearby tissues or distant sites. A clinical stage is assigned based on the 
results of a digital rectal exam, serum prostate specific antigen (PSA), and 
Gleason Score. As prostate cancer is generally a slow growing cancer, low-grade 
cases confined to the prostate capsule are often treated with “watchful waiting”. 
With watchful waiting the patient is closely monitored with regular PSA 
screenings, physical exams, and in some cases, biopsies, to determine if the 
cancer is growing. Cases of prostate cancer that remain confined to the prostate 




treated with local therapy such as prostatectomy or radiation. In most cases this 
treatment is curative; however there are cases of aggressive prostate cancer, 
which evade treatment. Prostate cancer recurrence is often detected by routine 
PSA screenings following treatment. A serum PSA result of 0.4ng/mL is 
indicative of biochemical recurrence and therefore disease relapse (American 
Joint Committee on Cancer, 2010; American Cancer Society, 2005). The 
challenge of prostate cancer diagnosis and treatment lies in predicting the 
potential of a given cancer to be an aggressive cancer. Unlike breast cancer, for 
which the presence or absence of HER2, ER, and PR serve as prognostic 
factors, there are no biomarkers that have been established as prognostic factors 
for prostate cancer beyond serum PSA determination. Therefore, there is a great 
need for prognostic biomarkers that can assist in estimating the likelihood of 
prostate cancer aggressiveness.   
 The glandular tissue of the prostate is comprised of ducts and acini that 
are lined by a simple cuboidal epithelium facing the lumen of the glands. In 
addition to this secretory component, two other specialized cells are an integral 
part of the prostate glandular structures, namely the basal cells and the 
neuroendocrine cells (Abate-Shen et al., 2000; Bonkhoff, 1996). The luminal cells 
secrete prostate specific antigen (PSA) and represent the functional unit of the 
organ. These cells form a continuous layer which lies on top of the basal cells. 
The basal cells are characterized by the expression of high molecular weight 
cytokeratins and p63. Dispersed throughout the acini is the third cell population, 




 Tumor initiation in the prostate is thought to be generated by the 
transformation of an epithelial cell precursor that develops into a premalignant 
lesion known as prostatic intraepithelial neoplasia (PIN) (Brawer, 1992). PIN is 
characterized by dysplasia — loss of normal cellular architecture — and 
proliferation of the transformed cells which usually display the luminal phenotype, 
namely they secrete PSA (Brawer, 1992). In PIN, which can be classified as low 
grade or high grade, the basal cell layer is usually lost or presents as a 
discontinuous layer (Brawer, 1992; Bostwick et al., 1993). Low-grade PIN lesions 
are described as having relatively “normal” appearing cells, being on some 
occasions difficult to distinguish from hyperplastic epithelium (Eble et al., 2004).  
High-grade PIN lesions, which are sometimes regarded as carcinoma in situ, 
display abnormal nuclei with prominent nucleoli, similar to those found in 
prostatic adenocarcinomas (Brawer, 1992; Bonkoff et al., 1996). Tumors derived 
from high grade PIN lesions have been reported to be more aggressive in nature 
(Wilcox et al., 1998). The progression from PIN to an invasive adenocarcinoma is 
marked by the percolation of tumor cells from well-defined glandular structures 
into the surrounding stroma (Eble et al., 2004; Bonkhoff, 1996). Further tumor 
progression is marked by the spread of malignant cells locally to seminal vesicles 
and perineural invasion, followed by metastatic disease to lymph nodes and later 







9. E-cadherin and Cancer 
 While in many cases organ confined cancers are associated with a high 
survival rate, metastatic cancers are responsible for the vast majority of all 
cancer related deaths. This is clearly illustrated in the case of prostate cancer 
where there is a reported 100% five-year survival rate for prostate cancer that is 
confined to the prostate, while the five-year survival rate drops dramatically to 
31.7% for prostate cancer that has metastasized to a distant site (American 
Cancer Society, 2009). As mentioned previously, the first step in metastasis is 
local invasion, where malignant cells first invade the surrounding stroma and 
then progressively move into local tissues. In order to travel to distant sites, 
malignant cells must enter into the circulatory system by undergoing 
intravasation, survive in the circulation, undergo extravasation upon reaching the 
distant site, and successfully establish a tumor colony at the distant site (Nguyen 
et al., 2009). The metastatic pathway presents a malignant cell with enormous 
challenges; accordingly there are relatively few cells that can survive all stages of 
the pathway. Those malignant cells that do survive must rapidly adopt properties 




that will allow for their continued survival in a variety of new cellular 
environments.  
 In order to initiate the process of invasion, a cancer cell must detach itself 
from the primary tumor and adopt migratory properties that allow it to move into 
the surrounding stroma. In tumors of an epithelial origin, this initial detachment 
from the primary tumor is thought to be largely mediated by the downregulation 
or loss of E-cadherin based adherens junctions. The downregulation or loss of E-
cadherin itself is a common feature of a variety of cancers, including prostate 
cancer, and can be caused by loss of heterozygosity (LOH), mutations, 
epigenetic silencing, transcriptional silencing, or increased endocytosis and 
proteolysis (Rubin et al., 2001; Berx and van Roy, 2009). Germline mutations of 
E-cadherin have been reported in familial gastric cancer, and in many cases 
these mutations are accompanied by promoter hypermethylation of the remaining 
allele thereby leading to a loss of E-cadherin expression (Guilford et al., 1998; 
Machado et al., 2001). Additionally, somatic genetic aberrations of E-cadherin, 
including LOH and mutations, have been identified in a variety of human cancers 
including diffuse gastric cancer, lobular breast cancer, bladder cancer, and 
prostate cancer (Becker et al., 1994; Berx et al., 1995; Taddei et al., 2000; Latil 
et al., 1997; Elo et al., 1997; Strathdee, 2002).  
 Several in vitro and in vivo studies have demonstrated a role for E-
cadherin in the progression of cancer to an invasive and metastatic state.  In vitro 
analysis shows that the introduction of E-cadherin expression in cancer cell lines 




was restored in the presence of anti-E-cadherin antibodies that block E-cadherin 
mediated adhesion (Vleminckx et al., 1991). In vivo analysis of a transgenic 
mouse model of pancreatic β-cell cancer (Rip1Tag2) shows that E-cadherin is 
expressed in well-differentiated adenomas but lost in invasive carcinomas (Perl 
et al., 1998). When E-cadherin expression was maintained in double transgenic 
mice that expressed E-cadherin in pancreatic β-cells (Rip1Tag2;Rip1E-cad) the 
incidence of carcinoma was significantly reduced. Conversely, when E-cadherin 
expression was lost in double transgenic mice expressing a dominant negative 
form of E-cadherin (Rip1Tag2;Rip1dnE-cad), the incidence of carcinoma 
increased dramatically and 25% of the double transgenic mice developed 
metastatic lesions. Additionally, a compound mutant mouse model of invasive 
lobular carcinoma with conditional deletion of E-cadherin in combination with 
epithelium-specific knock-down of p53 (K14Cre;Cdh1F/F; Trp53F/F) was found to 
develop invasive and metastatic mammary carcinomas (Derksen et al., 2006). 
Interestingly, the knock down of p53 alone results in relatively large mammary 
carcinomas that are generally not invasive, while the conditional deletion of E-
cadherin alone results in hyperproliferation, but not in tumor formation. These 
findings suggest that the loss of E-cadherin is not involved in tumor initiation, but 
is required for the progression to an invasive and metastatic state. Additionally, 
the tumor vasculature in the compound mutant mice was found to be significantly 
more extensive than that found in mutant mice expressing E-cadherin, and 
conditioned medium from cultured K14Cre;Cdh1F/F; Trp53F/F  cells induced 




E-cadherin in tumor angiogenesis and imply that the loss of E-cadherin results in 
the secretion of a factor that contributes to angiogenesis. The findings of Derksen 
et al. are further supported by compound mutant mouse models of non-small-cell 
lung carcinoma with conditional deletion of E-cadherin or expression of dominant 
negative E-cadherin in combination with the overexpression of C-RAF in type II 
alveolar pneumocytes (SP-C C-RAF BXB/SP-C rtTA/Tet-O-cre/cdh1flox/flo or SP-C 
C-RAF BXB/SP-C rtTA/Tet-O dn E-cadherin) (Ceteci et al., 2007). These 
compound mutant mice develop invasive carcinomas that metastasize into 
regional lymph nodes and bone marrow. Much like the Derksen et al. mouse 
model of invasive lobular carcinoma, mice overexpressing C-RAF alone develop 
multiple lung adenomas that do not progress to an invasive state, while the loss 
of E-cadherin alone leads to hyperproliferation but not tumor formation, further 
supporting the role of E-cadherin in the progression to an invasive state. 
Additionally, increased tumor angiogenesis was observed in compound mutant 
mice and this increase was associated with β-catenin induced expression of 
VEGF-A, VEGF-C and VEGFR-3, further supporting the role of E-cadherin in 
tumor angiogenesis. Taken together, these results suggest that the loss of E-
cadherin plays a causal role in the progression of tumors to a malignant and 
invasive state as well as in tumor angiogenesis.  
 
10. Desmosomes in Disease and Cancer 
 The importance of desmosomal cadherins in adult tissues is highlighted by 




tissues that undergo a high degree of mechanical stress and therefore rely on 
desmosomes for the maintenance of their integrity. Mutations in DSG1 are 
associated with striate palmoplantar keratoderma (PPKS), a rare autosomal 
dominant disorder characterized by thickening of the skin on the palms and soles 
(Rickman et al., 1999; Barber et al., 2006). Mutations in DSG2 and DSC2 are 
associated with arrythmogenic right ventricular cardiomyopathy (ARVC), an 
autosomal dominant disorder characterized by progressive myocardial atrophy 
with fibrofatty myocardial replacement of myocytes by adipocytes in the right 
ventricle (Awad et al., 2006; Pilichou et al., 2006; Syrris et al., 2007; Heuser et 
al., 2006). DSC2 is also associated with an autosomal recessive form of ARVC 
that is accompanied by PPKS and wooly hair (Simpson et al., 2009). Mutations in 
DSG4 are associated with localized autosomal recessive hypotrichosis, a 
disorder in which compromised hair shaft integrity results in hypotrichosis of the 
scalp, chest, arms, and legs (Kljuic et al., 2003). Mutations in DSG4 have also 
been associated with monilethrix-like hypotrichosis, a disorder in which affected 
hairs have a beaded appearance and break easily thereby resulting in alopecia 
(Schweizer, 2006; Shimomura et al., 2006; Zlotogorski et al., 2006; Schaffer et 
al., 2006). Additionally, the autoimmune blistering disorders pemphigus foliaceus 
and pemphigus vulgaris are caused by autoantibodies that target and block the 
function of DSG1 and DSG3, respectively (Amagai et al., 1999). 
  While clearly important in maintaining the integrity of adult tissues, the 
role of desmosomal cadherins in the progression of cancer is less well 




cadherin gene cluster has been reported in esophageal cancer as well as head 
and neck squamous cell carcinoma (Karkera et al., 2000; Takebayashi et al., 
2000).  Alterations in the expression of desmosomal cadherins have been 
reported for a variety of cancers. Reduced expression of DSG2 has been 
reported in gastric cancer and pancreatic cancer (Biedermann et al., 2005; 
Yashiro et al., 2006; Ramani et al., 2008). Additionally, the hypermethylation of 
the DSC3 promoter was associated with reduced expression of DSC3 in breast 
cancer (Oshiro et al., 2005). Conversely, overexpression of DSG2 and DSG3 has 
been reported in squamous cell carcinomas of the skin as well as head and neck 
cancer, respectively (Kurzen et al., 2003; Chen et al., 2007). Desmosomal 
cadherin switching has also been reported in colorectal cancer, where reduced 
expression of DSC2 was associated with de novo expression of DSC1 and DSC3 
(Khan et al., 2006). There is a lack of functional evidence regarding the role of 
desmosomal cadherin based adhesion in cancer. However, in vitro analysis of a 
non-adhesive, invasive fibroblast cell line shows that the expression of 
desmosomal cadherins and plakoglobin was able to generate adhesion and 
reduce the invasive capacity of the cell line (Tselepis et al., 1998). Treatment of 
these cells with peptides that blocked the desmosomal cadherin adhesion site 
both blocked adhesion and restored invasive capacity, suggesting that the 
observed adhesion and reduced invasive capacity were desmosomal cadherin 
specific. These results illustrate the possibility that desmosomal adhesion may 
result in a similar impaired invasive capacity of cancer cells, and that the loss of 




11. EMT and Cancer 
 While the first step in the metastatic cascade relies on the ability of 
malignant cells to detach themselves from a primary tumor before migrating into 
the surrounding stroma, ultimately these cancer cells must again form a tumor 
upon arrival at a distant site. Though the loss of adhesion is useful in the initial 
stages of metastasis, the permanent loss of adhesion may ultimately impair 
metastatic tumor formation. Indeed, while the loss of adherens junctions is a 
frequent occurrence in primary tumors, re-expression of adherens junction 
proteins is often found in metastatic tumors (Bukholm et al., 2000).  
 Maintaining a dynamic regulation of anchoring junctions as opposed to 
enforcing their permanent loss may therefore offer a selective advantage to the 
metastasizing cancer cell. Epithelial-mesenchymal transition followed by 
mesenchymal-epithelial transition (MET) is one such way a cancer cell could 
maintain a dynamic regulation of its anchoring junctions (Fig. 5). Though clearly 
essential in early development, the role of EMT in cancer remains controversial. 
This is mainly due to the difficulty of identifying a cancer cell that has undergone 
EMT in a primary human tumor sample. Most EMT markers are expressed in 
either epithelial or mesenchymal cells making it impossible to distinguish an 
epithelial cell that has undergone EMT and migrated into the surrounding stroma 






Figure 5: EMT in the progression of cancer (Thiery, 2002) 
 
 Despite the controversy, the loss of E-cadherin expression remains an 
underlying hallmark of both EMT and tumor progression. Additionally, much like 
EMT in early development, the loss of E-cadherin in the progression of cancer 
has been linked to transcriptional repression via effectors of EMT such as Snail, 
Slug, and Twist. The expression of Snail in breast cancer has been associated 
with high-grade tumors, lymph node metastasis, reduced E-cadherin expression, 
and disease recurrence (Blanco et al., 2002; Cheng et al., 2001; Moody et al., 
2005). The expression of Snail has also been associated with the downregulation 




expression in mouse and human cancer cell lines has shown that the expression 
of Snail is inversely correlated with the expression of E-cadherin (Cano et al., 
2000). Further analysis of human cancer cell lines has shown that the induction 
of Snail expression in a colon cancer cell line leads to a significant reduction in 
the level of E-cadherin mRNA expression, while reduced Snail expression in a 
pancreatic cancer cell line results in restored E-cadherin expression (Batlle et al., 
2000).   
 The expression of Slug, a member of the Snail family of zinc finger 
transcription factors, has been associated with metastasis and disease 
recurrence in breast cancer, and has been reported to be an independent 
prognostic factor for colorectal cancer (Martin et al., 2005; Shioiri et al., 2006). In 
lung cancer, Slug was associated with disease relapse and shortened patient 
survival (Shih et al., 2005). Additionally, in esophageal squamous cell carcinoma 
Slug expression was inversely correlated with E-cadherin expression and 
associated with poor clinical outcome (Uchikado et al., 2005). In vitro analysis 
has shown that Slug is able to bind E-box elements in the E-cadherin promoter, 
and represses the expression of both endogenous E-cadherin as well as an E-
cadherin reporter gene construct in a dose dependent manner in human breast 
cancer cell lines (Hajra et al., 2002). Additionally, the stable expression of Slug 
leads to transcriptional repression of E-cadherin in MDCK cells (Bolos et al., 
2002). It was demonstrated that this transcriptional repression was mediated by 
the binding of Slug to E-boxes in the E-cadherin promoter, however the binding 




stable expression of Slug in the rat bladder carcinoma NBT-II cell line results in 
the disappearance of DP and DSG from sites of cell-cell contact, while the 
expression of E-cadherin is not significantly downregulated in these cells 
(Savagner et al., 1997).  Taken together these results suggest that Slug can 
induce the loss of cell-cell adhesion in cancer by downregulating the expression 
of either E-cadherin or desmosomal proteins depending on the cellular context.  
  
12. The PI3K/AKT Signaling Pathway and Cancer 
 As mentioned previously, the PI3K/AKT signaling pathway is crucial for 
the regulation of processes such as proliferation and survival in normal cells. 
These processes are also extremely useful for cancer cells, accordingly the 
aberrant activation of the PI3K/AKT signaling pathway is a frequent occurrence in 
human cancers. One of the most commonly altered genes in the PI3K/AKT 
signaling pathway is the PTEN tumor suppressor gene which was originally 
identified by mapping homozygous deletions of chromosome 10q23 in primary 
breast tumors (Li et al., 1997). Loss of heterozygosity (LOH) at chromosome 
10q23 is a frequent occurrence in a variety of human cancers, such as breast 
cancer, melanoma, gastric cancer, and prostate cancer (Feilotter et al., 1999; 
Reifenberger et al., 2000; Byun et al., 2003; Cairns et al., 1997). In prostate 
cancer it has been reported that up to 62% to 65% of cases show LOH of 
chromosome 10q23-25 (Gray, 1995; Lacombe et al, 1996). Additionally, LOH 




metastasis that percentage increased to 60%, supporting the idea that PTEN is 
associated with prostate cancer progression (Cairns et al., 1997).  
 Though inactivation of the PTEN tumor suppressor is perhaps the most 
notorious alteration of the PI3K/AKT signaling pathway, alterations of other 
members within the pathway have also been detected. The AKT family is 
comprised of three genes encoding three AKT isoforms (AKT1, AKT2 and AKT3), 
all of which are similar in structure and size, and regulated by similar 
mechanisms (Scheid and Woodgett, 2001). In breast cancer, colorectal cancer, 
ovarian cancer, and lung squamous cell carcinoma it has been reported that 
AKT1 is aberrantly activated via a somatic mutation of its PH domain (E17K) 
which results in the localization of AKT1 to the plasma membrane (Carpten et al., 
2007; Malanga et al., 2008; Boormans et al., 2010). Additionally, rare 
amplification of AKT1 has been reported in gastric cancer and prostate cancer 
(Staal et al., 1987; Kirkegaard et al., 2010). Further, the overexpression of AKT1 
has been reported in thyroid cancer, prostate cancer, breast cancer, and ovarian 
cancer (Ringel et al., 2001; Sun et al., 2001). 
 The significance of the PI3K/AKT signaling pathway in prostate cancer 
was recently highlighted by the work of Taylor et al. who utilized a combination of 
DNA copy number analysis, mRNA expression analysis, and resequencing 
analysis to perform the most comprehensive genomic profiling of prostate cancer 
to date (Taylor et al., 2010). The results of this profiling show that PI3K/AKT 
signaling is altered in 42% of primary prostate cancers and 100% of metastatic 




observed, confirming the previously reported loss of PTEN in prostate cancer. 
While mutations in PIK3CA were rarely detected, the aberrant upregulation of 
PIK3CA was detected via mRNA expression analysis. This upregulation, in 
combination with the observed downregulation of inhibitors of PI3K/AKT signaling 
such as PTEN, INPP4B, and PHLPP, results in the aberrant activation of 
PI3K/AKT signaling. Taken together these results suggest that the aberrant 
activation of the PI3K/AKT signaling pathway is associated with the progression 
of prostate cancer to a metastatic state.  
 The importance of the PI3K/AKT signaling pathway in prostate cancer has 
also been demonstrated by mouse models of prostate cancer harboring Pten 
mutations such as the heterozygous Pten+/- knock out mouse model which 
develops preneoplastic lesions with hyperplastic-dysplastic features in several 
tissues including the prostate (Di Cristofano, 1998; Di Cristofano 2001).  Further, 
Pten compound mutant mouse models such as the Nkx3.1;Pten mouse model, 
show high grade PIN and invasive prostatic carcinoma lesions, while the  
Cdkn1b-/-;Pten+/-  mouse model also shows invasive prostate cancer (Kim et al., 
2002; Abate-Shen et al., 2003; Di Cristofano et al., 2001). Interestingly, prostate 
neoplasia is dramatically inhibited in the compound Pten+/-;Akt1-/- mutant mouse 
model which demonstrates the significance of AKT1 as a major effector of the 
PI3K/AKT signaling pathway in prostate cancer (Chen et al., 2006). Further, the 
transgenic MPAKT mutant mouse model of prostate cancer in which the 
expression of constitutively active Akt1 is driven by the prostate specific rat 




development in MPAKT mice is strikingly similar to that observed in the 
heterozygous Pten+/- knock out mouse model, further illustrating the significance 
of AKT1 mediated signaling in the development of prostate cancer (Majumder et 
al., 2003).     
  
13. The PI3K/AKT Signaling Pathway in EMT and Cancer 
 The PI3K/AKT signaling pathway has been linked to EMT in cancer. In 
vitro analysis of the MCF-10A breast cancer cell line has shown that cells 
overexpressing IGF-IR in which AKT1 has been downregulated via RNAi appear 
to undergo EMT and have enhanced cell migration (Irie et al., 2005). This 
phenotype is suppressed by the downregulation of AKT2, suggesting that EMT 
and cell migration are a result of AKT2 activity. Further, in vitro analysis of cell 
lines derived from mammary epithelial tumors induced by ErbB2 in either Akt+/+ 
or Akt-/- mice (i.e. ErbB2;Akt+/+ or ErbB2;Akt-/- mice) has shown that Akt+/+ cell 
lines display a lack of polarization and enhanced migration (Ju et al., 2007). 
These EMT-like features are absent in Akt-/- cell lines, suggesting that AKT1 is 
also able to promote an EMT-like phenotype in breast cancer cell lines. 
Additionally, AKT may have a role in the loss of E-cadherin expression as it has 
been shown that expression of constitutively active Akt in squamous cell 
carcinoma lines leads to a downregulation of E-cadherin mRNA expression 
(Grille et al., 2003). Interestingly, this same study showed that there was a 
mislocalization of desmoplakin, such that it displayed granular staining in the 




cadherin may be mediated via Snail as constitutively active Akt was shown to 
induce the expression of Snail mRNA. The activation of AKT signaling has also 
been shown to result in the stabilization of Snail through the inhibition of GSK3β, 
a kinase that inhibits Snail through phosphorylation at two consensus motifs 
which then leads to the ubiquitination and subsequent degradation of Snail (Zhou 
et al., 2004). Taken together this data suggests that the activation of AKT in 
cancer cells leads to an EMT-like phenotype which includes a loss of E-cadherin 
expression that may be mediated via transcriptional repression by Snail.   
 
14. Work Described in this Thesis 
 My doctoral studies were focused on examining the role of cell-cell 
adhesion in the progression of prostate cancer as well as the mechanism by 
which this adhesion is regulated. While most studies of cell-cell adhesion in 
cancer have focused on adherens junctions alone, I sought to conduct a more 
comprehensive analysis of cell-cell adhesion in prostate cancer by broadening 
my focus to include both adherens junctions and desmosomes. Prior to this 
study, the expression profile of desmosomal cadherins in the prostate was 
unknown. I therefore began this study with an examination of the expression of 
desmosomal cadherins in prostate tissue as well as prostate cancer cell lines. In 
chapter II of this study I describe this analysis of the desmosomal cadherin 
expression profile in normal prostate tissue and prostate cancer cell lines, and 
discuss the how the results of this analysis led me to focus on the expression of 




The reduction or loss of E-cadherin expression has been reported in a 
variety of cancers — including prostate cancer — and previous studies have 
demonstrated that the formation of adherens junctions precedes that of 
desmosomes both in early development as well as in the de novo assembly of 
cell-cell anchoring junctions. I therefore hypothesized that the loss of E-cadherin 
based adherens junctions in prostate cancer results in the reciprocal loss of 
desmosomal adhesion. I describe the functional analysis used to examine this 
hypothesis and the surprising results of this analysis as well as the implications 
of these results with respect to anchoring junction assembly in chapter III. 
Additionally, in this chapter I describe the functional analysis used to examine the 
effects of the loss of E-cadherin expression on the formation of both primary and 
metastatic tumors. Further, I discuss a novel role for E-cadherin as a tumor 
promoter, in addition to its established role as a tumor suppressor, suggested by 
the results of this functional analysis.  
While the reduction of E-cadherin expression has been reported in primary 
prostate cancer, the results of the analysis performed in chapter III illustrate a 
dual role for E-cadherin in the progression of prostate cancer, suggesting that the 
repression of E-cadherin expression observed in primary prostate cancer may 
need to be a transient event. This potential requirement for the transient 
repression of E-cadherin in the progression of prostate cancer coupled with the 
demonstrated significance of PI3K/AKT signaling in the progression of prostate 
cancer and the association of this signaling with EMT-like events in several other 




EMT-like transcriptional repression of E-cadherin via Snail in prostate cancer.  I 
describe the functional analysis performed to examine this hypothesis and 
discuss the implications of this analysis regarding the regulation of both E-
cadherin based adherens junctions and DSG2 based desmosomes in prostate 
cancer in chapter IV.  
Though the reduction of E-cadherin expression has been reported in 
primary prostate cancer, no large-scale study has yet examined the association 
of E-cadherin expression and biochemical recurrence in prostate cancer; and, as 
mentioned previously, the expression of DSG2 in prostate cancer had been 
unexplored to date. Chapter V describes the analysis of E-cadherin and DSG2 
expression in primary prostate cancer tissue performed for a large cohort of 
patients with prostate cancer who underwent radical prostatectomy. I discuss the 
demonstrated utility of these cadherins as markers of aggressive prostate 
cancer, and describe the analysis of pAKT and Snail expression performed for 
this cohort. The chapter concludes with a discussion of the results of this analysis 
regarding the regulation of E-cadherin based adherens junctions and DSG2 
based desmosomes in prostate cancer.  
The work presented in this thesis provides the first examination of the 
expression of desmosomal cadherins in both normal prostate tissue and prostate 
cancer, and suggests that the loss of E-cadherin and DSG2 expression in 
primary prostate cancer may be regulated by separate mechanisms. Further, this 
study provides evidence for a new role for E-cadherin in promoting the formation 




of E-cadherin in prostate cancer can be mediated by the PI3K/AKT signaling 
pathway. Finally, the work presented provides the first demonstration of the utility 































Expression of Desmosomal Cadherins in Normal Human Prostate and 





















While the presence of E-cadherin containing adherens junctions in the 
prostate is well established, and the presence of desmosomes in the prostate 
has been described, the expression profile of desmosomal cadherins in normal 
human prostate has not been well characterized, to date (Umbas et al., 1992; 
Fisher and Jeffrey, 1965). As mentioned previously, desmosomes are found in 
tissues that undergo a high degree of mechanical stress, and loss of 
desmosomal adhesion is associated with diseases affecting the skin, hair, and 
heart. The expression of desmosomal cadherins has been thoroughly 
characterized in the epidermis and hair follicle. The epidermis is a continuously 
self-renewing tissue that is made up of several cell layers. The basal layer is the 
epidermal cell layer closest to the dermis that directly contacts the basement 
membrane and contains the least differentiated keratinocytes; this layer is 
followed by the spinous layer, the granular layer, and the stratum corneum which 
is the most superficial of the epidermal cell layers and is comprised of the most 
differentiated dead keratinocytes (Kanitakas, 2002). As keratinocytes 
differentiate, the expression patterns of their keratins change. The less 
differentiated keratinocytes in the basal layer express keratins 5 and 14, while 
the more differentiated keratinocytes in the spinous layer express keratins 1 and 
10 (Ishida-Yamamoto et al., 2002). Like keratins, the expression pattern of 




differentiated keratinocytes in the basal layer express DSG2, DSC2, DSG3, and 
DSC3 while the more differentiated keratinocytes of the spinous layer express 
DSG1 and DSC1 (Yin and Green, 2004). Analysis of interfollicular epidermis via 
immunofluorescence (Bazzi and Getz et al., 2006) has shown that DSG4 is found 
in the highly differentiated upper spinous and granular layers. While the 
expression of DSG4 in the epidermis overlaps with that of DSG1 and DSC1 for 
the most part, it also extends beyond DSG1 and DSC1 expression into the 
uppermost cells of the granular layer (Figure 1 and 2).  
 
Figure1: Desmosomal cadherin expression in the human epidermis (Adapted from Fuchs 





Figure 2: Desmoglein expression in the human epidermis (Bazzi and 
Getz et al., 2006) 
 
The hair follicle (HF) is composed of concentric epithelial sheets that arise 
due to signaling from the dermal papilla to neighboring matrix cells which results 
in their proliferation and differentiation. As the matrix cells withdraw from the cell 
cycle they move away from the dermal papilla in concentric cylinders forming the 
three cell layers of the inner root sheath (IRS) — Henle’s layer, Huxley’s layer, 
and the IRS cuticle — and the three cell layers of the hair shaft — the hair 
cuticle, the cortex, and the medulla. The IRS is surrounded by the companion 
layer and outer root sheath (ORS), the latter of which is contiguous with the 
epidermis and is composed of the first matrix cells to lose contact with the dermal 
papilla during the original downward growth of the hair follicle (Fig. 4) (Fuchs et 
al., 2001). The expression of DSG1 is found in the IRS at the lower portion of the 




well as ORS in the region above the precortex. DSG3 is expressed in the lower 
precortical trichocytes as well as the ORS in the upper follicle and the medulla. 
DSG4 is found in the cells of the precortex and extends to the cortex and cuticle 
of the hair shaft, as well as the inner root sheath cuticle. Interestingly, DSG4 is 
the only desmoglein represented in the hair shaft cortex (Fig 5) (Bazzi et al., 
2006; Kurzen et al., 1998). Taken together with the observed expression of 
DSG4 in the epidermis, these findings indicate that DSG4 is uniquely expressed 
in the most highly differentiated and mechanically stressed cells of the epidermis 
and hair shaft.   
 
 
Figure 3: Anatomy of the hair follicle. (Adapted from Niemann and Watt,  
2002.)  




     
Figure 4: Expression of desmogleins in the hair follicle (Bazzi 
and Getz et al., 2006) 
   
 The expression of DSG2 is known to be ubiquitous in all desmosome 
forming tissues; however, the expression of the remaining desmosomal 
cadherins outside of the epidermis and hair follicle is poorly understood (Schafer 
et al., 1996). A study by Whittock and Bower in 2003 utilized RT-PCR to analyze 
the expression of DSG4 in a panel of tissues and found that DSG4 could be 
detected in several tissues including the prostate, suggesting that the 
desmosomal cadherin expression profile of the prostate may extend beyond the 
ubiquitous expression of DSG2. To examine this idea, in chapter II.2 I 




prostate and determined the cell type in which prostate specific desmogleins are 
expressed. Interestingly, only DSG2, DSC2, and DSG4 were found to be 
expressed in normal human prostate at both the RNA and protein level.  
 Though aberrant expression of desmosomal cadherins has been reported 
in several types of cancer as described in Chapter I.10, the expression of 
desmosomal cadherins in prostate cancer has not been thoroughly analyzed to 
date. In chapter II.3 I sought to determine whether the expression of prostate 
specific desmogleins is altered metastatic prostate cancer cell lines. While DSG2 
and DSG4 are expressed in normal human prostate, only DSG2 can be detected 
in the metastatic prostate cancer cell lines. I discuss the prostate specific 
desmosomal cadherin expression of DSG2, DSC2, and DSG4 in normal human 
prostate as well as the expression of DSG2 in metastatic prostate cancer cell 
lines in chapter II.4. The methods used to characterize the expression of 
desmosomal cadherins in normal human prostate and human metastatic prostate 




The Expression of Desmosomal Cadherins in Normal Human Prostate  
 The first goal of this study was to determine the desmosomal cadherin 
expression profile of normal human prostate tissue using RT-PCR and 
immunofluorescence analysis. RT-PCR analysis showed that most desmosomal 




prostate at the RNA level (Figure 5).  However, immunofluorescence analysis 
revealed that only the expression of DSG2, DSC2, and DSG4 could be readily 
and consistently detected in the prostate at the protein level (Figure 6).      
Figure 5: RT-PCR analysis of desmosomal cadherin expression in normal    
human prostate. Expression of mRNA can be detected for most desmosomal 






Figure 6: Immunofluorescence analysis of desmosomal cadherin expression in normal 
human prostate. DSG2 (A), DSG4 (B), and DSC2 (C) are detected at the cell border in 
normal human prostate. Cell border expression of DSG1 (D), DSG3 (E), DSC1 (F), and         





 Having established the expression of desmosomal cadherins in normal 
human prostate, the next goal of this study was to determine the cell type specific 
expression of DSG2 and DSG4. Co-immunofluorescence analysis was 
performed to examine the localization of DSG2 and DSG4 with K14 — a keratin 
specifically expressed in the basal cells of the prostate — and prostate specific 
antigen (PSA) — a protein secreted by the luminal cells of the prostate. Co-
immunofluorescence analysis of DSG2 and K14 shows that DSG2 is robustly 
expressed in the luminal cells of the prostate and that this expression rarely 
colocalizes with that of basal K14 expression (Figure 7A-C). The expression of 
DSG4 is very similar to that of DSG2, showing strong expression in the luminal 
cells, colocalization with luminal PSA expression, and rare colocalization with 
basal K14 expression (Figure 7D-I). While analysis of DSG2 and PSA expression 
could not be performed as the antibodies for these antigens were made in the 
same animal and are therefore incompatible, the expression of DSG2 was found 
to colocalize with that of DSG4 (Figure 7J-L). Taken together these results show 
that the expression of DSG2 and DSG4 is mainly restricted to the luminal cells of 








Figure 7: Co-immunofluorescence analysis of DSG2 and DSG4 and prostate cell type 
specific markers. DSG2 is expressed in the luminal cells and this expression rarely 
colocalizes with basal cell K14 expression (A-C). DSG4 is also expressed in the luminal 
cells and rarely colocalizes with basal cell K14 expression (D-F), however DSG4 
expression does colocalize luminal cell PSA expression. The expression of DSG4 also 






The Expression of DSG2 and DSG4 in Human Prostate Cancer Cell Lines  
 The discovery that DSG2 and DSG4 show a high level of expression in 
normal human prostate led me to ask whether these proteins were expressed in 
human prostate cancer cell lines. To examine this question, qRT-PCR was 
performed on metastatic human prostate cancer cell lines (Figure 8). The cancer 
cell lines utilized for this portion of the study include the LNCaP cell line, which 
was derived from a prostate cancer that metastasized to the lymph node; the 
PC3 cell line, which was derived from a prostate cancer that metastasized to the 
bone; and the DU145 cell line, which was derived from a prostate cancer that 
metastasized to the brain (Horoszewicz et al., 1980; Kaighn et al., 1979; Stone et 
al., 1978). The BPH-1 cell line served as a positive control for this study. This cell 
line is an immortalized, non-tumorigenic prostatic epithelial cell line derived from 
a patient with benign prostatic hyperplasia, a condition which affects the stroma 
of the prostate (Hayward et al., 1995). The results of this qRT-PCR analysis 
show that that DSG2 is expressed in all cell lines examined. Further, the 
expression of DSG2 is greater in all the metastatic prostate cancer cell lines 
examined than it is in the non-tumorigenic BPH-1 control.  Conversely, though 
expressed in the BPH-1 control, the expression of DSG4 is undetectable in all 





Figure 8: qRT-PCR of DSG2 and DSG4 in human metastatic prostate cancer cell lines. 
DSG2 expression is detected in all cell lines examined, while DSG4 expression is not 
detected in any of the prostate cancer cell lines. Scale bars represent standard deviation;   
(**) represents P < 0.01; (***) represents P < 0.001. 
 
 
 Next, immunofluorescence analysis was utilized to examine the 
expression of DSG2 in these metastatic human prostate cancer cell lines at the 
protein level (Figure 9). Cell border expression of DSG2 was detected in BPH-1, 
LNCaP, and DU145 cells. However, PC3 cells lack the expression of DSG2 at 
the cell border, while a small population of cells shows only a diffuse granular 
staining for DSG2 in the cytoplasm. These results are consistent with reported 
ultrastructural analysis of prostate cancer cell lines grown in spheroid cultures 
showing that LNCaP cells form extensive cell-cell contacts with detectable 




with few cell-cell contacts (Hedlund et al., 1999). The results of the qRT-PCR and 
immunofluorescence analysis show that the expression of DSG4 is absent in 
prostate cancer cell lines, while the expression of DSG2 is present. Further, in 
most of the prostate cancer cell lines examined, DSG2 localizes to the cell border 
suggesting that desmosomal formation is retained in most metastatic prostate 






Figure 9: Immunofluorescence analysis of DSG2 in metastatic prostate cancer cell 
lines. DSG2 is expressed at the cell border of LNCaP (B) and DU145 (D) cells, 















 Prior to this study, the expression of desmosomal cadherins in normal 
human prostate had not been thoroughly examined. The results presented in this 
chapter show that while most desmosomal cadherins are expressed in the 
human prostate at the RNA level, only DSG2, DSC2, and DSG4 are consistently 
expressed at a high level in normal human prostate at the protein level. Though 
desmosomal cadherin mediated cell-cell adhesion has been shown to occur via 
heterophilic interactions between the extracellular domains of desmogleins and 
desmocollins, this idea of heterophilic interaction is somewhat controversial, as 
homophilic binding of desmosomal cadherins has also been reported (Chitaev et 
al., 1997; Syed et al., 2002). Biochemical analysis of the binding affinity of 
desmosomal cadherins shows that desmocollins are able to engage in 
homophilic and heterophilic interactions, while desmogleins preferentially engage 
in heterophilic interactions with desmocollins (Syed et al., 2002). The observation 
that desmogleins preferentially interact with desmocollins in vitro suggests that 
desmosomal cadherin based adhesion in the prostate may be mediated via 
heterophilic interactions of DSG2 and DSG4 with DSC2. 
 Further, the expression of DSG2 and DSG4 was found to be largely 
restricted to the luminal cells of the prostate. In both the epidermis and the hair 
shaft, DSG4 is found in cells that undergo the highest degree of mechanical 
stress within their respective tissues. While the prostate epithelium is not 




of this epithelium to the movement of prostatic fluid does subject the luminal cells 
to a mechanical force. Given that this tissue is relatively dormant with respect to 
cell proliferation, luminal cells must be protected from this regular mechanical 
force to prevent them from being sloughed off. The expression of DSG4 in the 
most mechanically stressed layers of the epidermis and hair shaft suggests that 
this desmoglein may provide for stronger adhesion than the other desmoglein 
isoforms. The presence of DSG4 in the human prostate may then provide an 
additional level of adhesive strength in the desmosomes of luminal cells beyond 
that provided by DSG2 alone. Interestingly, the expression of DSG2 is present in 
metastatic prostate cancer cell lines in vitro, while the expression of DSG4 is 
absent in all cancer cell lines examined. If the presence of DSG4 does in fact 
confer an additional degree of adhesive strength, this finding may reflect a need 
for cell-cell adhesion in metastatic cells that is strong enough to maintain the 
integrity of a metastatic tumor, yet not so strong as to prevent invasive behaviors.   
 In summary, the results presented in this chapter provide the first 
characterization of desmosomal cadherin expression in normal human prostate 
and metastatic prostate cancer cell lines. Given that DSG4 is undetectable in 
metastatic prostate cancer cell lines coupled with limitations of the antibodies 
generated against DSG4 to usage on only frozen tissue samples, DSG4 will not 
be examined beyond this chapter. However, the role of DSG2 in aggressive 








Materials and Methods 
Cell Culture and RNA Isolation 
 The BPH-1 cell line (a generous gift from Dr. Ralph Buttyan) was cultured 
in RPMI with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA). The 
DU145 human prostate cancer cell line (ATCC, Manassas, VA, USA) was 
cultured in MEM with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). 
The PC3 human prostate cancer cell line (ATCC, Manassas, VA, USA) was 
cultured in F12K with 10% FBS (Invitrogen, Carlsbad, CA, USA). The LNCaP 
human prostate cancer cell line (ATCC, Manassas, VA, USA) was cultured in 
RPMI with 10% FBS (Invitrogen, Carlsbad, CA, USA).       
 To isolate RNA, cells grown four days past confluency were washed in 1X 
PBS, trypsinized, and pelleted via centrifugation. The cell pellets were 
resuspended in 1X PBS and then pelleted via centrifugation to wash. This wash 
step was repeated twice to remove all traces of media prior to harvesting RNA. 
RNA was then harvested using the RNeasy Mini Kit and QIAshredder following 
the manufacturer’s protocol entitled “Purification of Total RNA from Animal Cells 
Using Spin Technology” (Qiagen, Valencia, CA, USA).  
  
Antibodies 
 Anti-DSG3 (clone 5H10) and DSG1 (clone 27B2) mouse monoclonal 




gift from Dr. James Wahl; both were used at a dilution of 1:10 for 
immunofluorescence analysis (Wahl, 2002). Anti-DSG2 mouse monoclonal 
antibody (clone 10G11) was purchased from ARP, Inc™ (Belmont, MA, USA) 
and used at a dilution of 1:50 for immunofluorescence analysis. Anti-DSG4 
guinea pig polyclonal antibody, anti-DSC1 mouse monoclonal antibody, and anti-
DSC3 mouse monoclonal antibody were generated by Dr. Lutz Langbein and 
given to us as a generous gift; the anti-DSG4 antibody was used at dilution of 
1:2000 while both the anti-DSC1 and anti-DSC3 antibodies were used at a 
dilution of 1:10 for immunofluorescence analysis. Anti-DSC2 mouse monoclonal 
antibody (clone 7G6) was purchased from Santa Cruz Biotechnology, Inc (Santa 
Cruz, CA, USA) and used at a dilution of 1:200 for immunofluorescence analysis. 
Anti-K14 rabbit polyclonal antibody was purchased from Covance (Princeton, NJ, 
USA) and used at a dilution of 1:1000 for immunofluorescence analysis. Anti-
PSA mouse monoclonal antibody was purchased from Dako (Carpinteria, CA, 
USA) and used at a dilution of 1:20 for immunofluorescence analysis. Alexa 
Fluor® 594 or Alexa Fluor® 488 secondary antibodies were purchased from 




 Total RNA for human skin and prostate was purchased commercially 
(Agilent Technologies Inc., Santa Clara, CA, USA). First strand cDNA was made 




(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions.  PCR 
was performed using Platinum PCR Supermix (Invitrogen, Carlsbad, CA, USA) 
and primers for the transcript of interest (listed in Table 1). The following PCR 
protocol was used: step 1: 94ºC for 3 min; step 2: 94 ºC for 30 sec, 56 ºC for 45 
sec, 72ºC for 2min; step 3: 72 ºC for 10 min; repeat step 2 for 34 cycles.  PCR 
products were electrophoresed on a 1% agarose/1X TBE gel containing ethidium 
bromide and visualized using Kodak Electrophoresis Documentation and 
Analysis System 120 Camera (Kodak, Rochester, NY, USA).  
 
Table 1: RT-PCR Primers and qRT-PCR Primers 
RT-PCR Primers 
Transcript Forward Primer Reverse Primer 
DSG1 5’-CACTCAGATTGTGCTGCAAAC-3’  5’-GTCCTGCAAATGTAGCCATTG-3’ 
DSG2 5’TCTTGAGGCCCTATGCAGTT-3’ 5’-GCTGCACTCAACTCTTCAAC-3’ 
DSG3 5’-GAGATGACTATGCAACAAGCT-3’ 5’-TTCTCTACATCTAGTCCTTGG-3’ 
DSG4 5’-ATGGATTGGCTCTTCTTCAGA-3’ 5’-ACTCTAAGCTCAAGAGGCCT-3’ 
DSC1 5’-GCGATGCTTGTCAGAAAGTTT-3’ 5’-GTTTTCTCTTGCTGACAGTAC-3’ 
DSC2 5’-CCTGAAAGAGTGCTTTACAGC-3’ 5’GCATCGAACAAGGAATTGGAG-3’ 
DSC3 5’-TTGGAAGAGTGCTTCAGGTCT-3’ 5’-ATTCTCTTGCATAGAGCAAGG-3’ 
β-actin 5’-GATGATGATATCGCCGCGCT -3’ 5’-CCTGGATAGCAACGTACATG-3’ 
qRT-PCR Primers 
DSG2 5’-ATCAATGCAACAGATGCAGATGA-3’ 5’-TGTCAAAGTGTAGCTGCTGTGT-3’ 
DSG4 5’-CTGAATTCACGGGGTGAAGATT-3’ 5’-CATCTGCATCTGTGGCACATAA-3’ 







 RNA was harvested from cell lines of interest as described. First strand 
cDNA was made using Oligo dT and the SuperScript® III First-Strand Synthesis 
System (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s 
instructions. qRT-PCR was performed on a Stratagene Mx3005P machine and 
analyzed using Stratagene MxPro QPCR software (Stratagene, Santa Clara, CA, 
USA). All reactions were performed using QuantiTect™ SYBR® Green PCR 
Master Mix (Qiagen, Valencia, CA, USA), 200nM primers (shown in Table 1), and 
10ng cDNA in a 20 µL reaction volume. The following PCR reaction was used: 
step 1: 95 ºC for 10 min; step 2: 95 ºC for 15 sec, 60 ºC for 1 min; repeat step 2 
for 40 cycles. All samples were run in quadruplicate, and samples were 
normalized against an endogenous internal control, β-actin.    
 
Immunofluorescence—Frozen Tissues and Cell Lines 
 Frozen normal human prostate tissue slides were obtained from the 
Columbia Tumor Bank Service in accordance with the Institutional Review Board 
of Columbia University Protocol #AAAB2447. Cell lines were grown on glass 
coverslips (Fisher, Pittsburgh, PA, USA) in 6-well tissue culture plates (BD 
Falcon, Bedford, MA, USA). Slides/coverslips were fixed in cold 100% methanol 
for 15 min at -20˚C. Slides/coverslips were then fixed in cold 100% acetone for 2 
min at -20˚C. Slides/coverslips were washed in 1X phosphate buffered saline 




temperature for 5 min, and washed again in 1X PBS with agitation. 
Slides/coverslips were incubated in 0.1% Triton X-100/ 1% bovine serum albumin 
(BSA)/ 1X PBS block at room temperature for 1 hour. Block was then aspirated, 
primary antibody was added, and slides/coverslips were incubated overnight at 
4ºC. The following day slides/coverslips were washed in 1XPBS with agitation, 
then a 1:600 dilution of secondary antibody, either Alexa Fluor® 594 or Alexa 
Fluor® 488 (Invitrogen, Carlsbad, CA, USA), was added and slides/coverslips 
were incubated at room temperature for 45 min. Slides/coverslips were then 
washed in 1XPBS with agitation, immersed briefly in water and mounted using 
VECTASHIELD® mounting medium with DAPI (Vector Laboratories, Burlingame, 














































 The loss of E-cadherin is a common occurrence in a variety of cancers 
including prostate cancer. In contrast, while aberrant desmosomal cadherin 
expression has been reported in several cancer types, the status of desmosomal 
cadherin expression in prostate cancer has not been explored to date.  
 As described in chapter I, the formation of adherens junctions has been 
shown to precede that of desmosomes in both early development and in the de 
novo formation of anchoring junctions. Additionally, in vitro analysis has shown 
that desmosomes are able to form only in the presence of a classic cadherin 
(Lewis et al., 1997). The reported downregulation of E-cadherin expression in 
prostate cancer and the reduced desmosomal cadherin expression reported in 
several cancer types, coupled with the classic model of de novo anchoring 
junction assembly led me to hypothesize that the loss of E-cadherin based 
adherens junctions in prostate cancer results in the loss of desmosomal 
adhesion. In chapter II, I established that the expression of DSG2 is present in 
both normal human prostate and human metastatic prostate cancer cell lines. In 
this chapter I sought to examine desmosomal adhesion in a prostate cancer 
environment lacking adherens junctions by focusing on the expression of DSG2 




 In chapter III.2, I knocked down the expression of E-cadherin mRNA via 
the expression of an shRNAmir targeting E-cadherin in the DU145 prostate 
cancer cell line — a cell line that is positive for markers of both adherens 
junctions and desmosomes under normal conditions. I then characterized the 
expression of E-cadherin and DSG2 in the resulting EcadKD cell lines. 
Surprisingly, the expression of DSG2 remained relatively unperturbed even when 
E-cadherin expression was reduced to an almost undetectable level.  
 I next sought to examine the effects of disrupted adherens junction 
formation on tumorigenesis. In chapter III.3, I performed an in vivo tumorigenesis 
assay in NOD/SCID mice by injecting my cell lines of interest subcutaneously, 
allowing for tumor formation, and subsequently analyzing the resulting tumors for 
the expression of E-cadherin and DSG2. Interestingly, I found that the loss of E-
cadherin based adherens junctions results in a dramatic reduction in the size of 
tumors formed despite the retention of desmosomal adhesion.  
 My final goal for this portion of the study was to examine the effects of this 
E-cadherin knockdown on extravasation and metastatic tumor colony formation. 
In chapter III.4, I performed an in vivo metastasis assay by injecting my cell lines 
of interest into the lateral tail vein of NOD/SCID mice, allowing for tumor 
formation, and subsequently analyzing the lungs of the injected animals for the 
formation of metastatic tumor colonies. Again, the loss of E-cadherin based 
adherens junctions had a dramatic effect on both the amount and overall size of 
tumors formed in the lungs of injected animals despite the retention of 




cadherin based adherens junctions and desmosomal adhesion in vitro as well as 
the role of E-cadherin based adherens junctions and desmosomal adhesion in 
prostate tumorigenesis, extravasation, and metastatic tumor colony formation in 
vivo. The methods utilized for this portion of the study are described in chapter 




In Vitro Analysis of Desmosomes and the Loss of Adherens Junctions in 
Prostate Cancer 
 The first goal of this study was to test the hypothesis that the loss of E-
cadherin based adherens junctions in prostate cancer results in the loss of 
desmosomal adhesion. To accomplish this goal, I wanted to perform an in vitro 
examination of desmosomal adhesion in a prostate cancer environment lacking 
adherens junctions. The DU145 human metastatic prostate cancer cell line was 
utilized as the in vitro prostate cancer model system for this study. I chose to 
focus on this cell line, as cell border expression of both desmosomal (as 
described in chapter II.3) and adherens junction proteins are detected in the 
DU145 cell line under normal conditions (Mitchell et al., 2000).  
 To disrupt the formation of E-cadherin based adherens junctions in the 
DU145 cell line I utilized an shRNAmir targeting E-cadherin. DU145 cells were 
infected with an shRNAmir-E-cadherin retroviral construct and grown under 




cadherin construct (hereafter referred to as EcadKD cell lines) were selected and 
mRNA knockdown efficiency was analyzed via qRT-PCR (Figure 1).  Most 
mutant cell lines showed a significant reduction in E-cadherin expression, with 
EcadKD9 showing a 99.6% reduction in E-cadherin expression. Cell lines with 
>80% knockdown of E-cadherin expression were chosen for further analysis. The 
expression of E-cadherin was examined at the protein level via 
immunofluorescence analysis in EcadKD2, EcadKD3, EcadKD5, and EcadKD9 
(Figure 2). Consistent with the qRT-PCR results, the cell border expression of E-
cadherin was noticeably reduced in all EcadKD cell lines as compared to the 
DU145 parental cell line. Importantly, the most striking reduction of E-cadherin 
expression was found in EcadKD9 where the cell border expression of E-
cadherin was undetectable via immunofluorescence analysis and was shown to 







Figure1: qRT-PCR analysis of E-cadherin mRNA expression in DU145 cell lines stably 
expressing an shRNAmir-E-cadherin construct. EcadKD9 shows the most dramatic 
reduction of E-cadherin expression (99.6%). Scale bars represent standard deviation; (*) 





Figure 2: Immunofluorescence analysis of E-cadherin expression in EcadKD cell lines. All 
mutant cell lines examined show reduced expression of E-cadherin at the cell border as 
compared to the DU145 parental cell line (A-E). Notably, E-cadherin expression is 
undetectable at the cell border of EcadKD9 (E). Western analysis confirms the significantly 






 Having examined the expression of E-cadherin in the EcadKD cell lines, I 
next examined the expression of DSG2 via qRT-PCR in the EcadKD cell lines 
showing a >80% knockdown of E-cadherin expression (Figure 3). Interestingly, 
despite the dramatic reduction in E-cadherin expression, the level of DSG2 
expression in the EcadKD cell lines was relatively unaffected. Most notably, the 
level of DSG2 expression was only slightly lower (5.3%) in EcadKD9 than in the 
parental DU145 cell line. The expression of DSG2 at the protein level was then 
examined via immunofluorescence analysis in the EcadKD cell lines of interest 
(Figure 4). Consistent with the qRT-PCR findings, cell border expression of 
DSG2 was detected in all EcadKD cell lines examined. Importantly, the level of 
DSG2 in EcadKD9 was only slightly less than that of the parental DU145 cell line 
(Figure 4E, 4F).  
 In summary, the results of mRNA and protein expression analysis show 
that the expression of E-cadherin has been reduced to virtually undetectable 
levels in the EcadKD9 cell line. Unexpectedly, the expression of DSG2 is 
relatively unaffected by the reduction or loss of E-cadherin expression. This 
finding suggests that the formation of desmosomes in prostate cancer is not 
dependent upon the prior formation of adherens junctions. The effects of the loss 
of E-cadherin based adhesion in the presence of retained desmosomal adhesion 
on prostate tumorigenesis, extravasation, and metastatic tumor colony formation 






Figure 3: qRT-PCR analysis of DSG2 mRNA expression in DU145 cell lines stably 
expressing an shRNAmir-E-cadherin construct. The level of DSG2 expression is 
relatively unaffected in the EcadKD cell lines. Scale bars represent standard deviation; (*) 







Figure 4: Immunofluorescence analysis of DSG2 expression in EcadKD cell lines. All mutant cell 
lines examined show expression of DSG2 at the cell border (A-E). Western analysis confirms 
DSG2 protein expression in EcadKD9 cells at a level slightly lower than that of the DU145 









Chapter III.3  
 
In Vivo Tumorigenesis Analysis of Cell-Cell Adhesion in Prostate Cancer 
 Having found that the loss of E-cadherin based adherens junctions did not 
have an effect on the formation of DSG2 based desmosomes in the DU145 cell 
line in vitro, I next asked whether this loss of adherens junctions had an effect on 
the ability of the DU145 cell line to form tumors in vivo. Given that desmosomes 
are linked to the intermediate filament cytoskeleton and therefore provide a 
degree of strength greater than that of actin cytoskeleton linked adherens 
junctions, it is possible that desmosomal adhesion alone is sufficient to support 
the growing mass of cells that form a tumor. However, it is also possible that 
tumorigenesis may require a level of adhesion greater than that of desmosomal 
adhesion. To answer this question, I performed an in vivo tumorigenesis assay in 
which cells from the parental DU145 cell line and EcadKD9 were injected 
subcutaneously into the backs of age matched male immunodeficient NOD/SCID 
mice. Tumors were then allowed to grow for eight weeks at which point the mice 
were sacrificed and the tumors were collected for analysis. Two separate trials of 
the in vivo tumorigenesis assay were performed, and the combined results from 
these assays are discussed.  
 Interestingly, there was a striking difference between the size of the 
tumors formed by the parental DU145 cell line and those formed by EcadKD9 




5D) were large (1.33 cm3 ± 0.71) while the tumors formed by EcadKD9 (Figure 




Figure 5: In vivo tumorigenesis assay. Cells from the DU145 parental cell line (A, black 
arrow) and EcadKD9 (A, red arrow) were injected subcutaneously in NOD/SCID mice. 
The DU145 parental cell line produced large tumors (B and D) while EcadKD9 produced 





 Frozen OCT embedded sections of the tumors were then analyzed for the 
expression of E-cadherin and DSG2 via immunofluorescence to ensure that the 
cadherin expression profile observed in vitro was maintained in the tumors 
formed in vivo (Figure 6). Indeed the DU145 parental cell line formed tumors with 
robust expression of both E-cadherin and DSG2 at the cell-cell border (Figure 6A 
and 6C), while tumors formed by the EcadKD9 cell line showed robust 
expression of only DSG2 at the cell-cell border (Figure 6B and 6D). Faint 
expression of E-cadherin was sometimes detectable in the EcadKD9 tumors, 
though this expression was highly irregular as it was only detected in small areas 
of the tumor and the classic chicken-wire pattern of expression was not 
observed. Taken together these results strongly suggest that the loss of E-
cadherin based adherens junctions dramatically impairs prostate tumorigenesis. 
These results also suggest that the presence of DSG2 based desmosomal 







Figure 6: Immunofluorescence analysis of tumors formed by the DU145 parental cell line (A, C) 
and EcadKD9 (B, D). E-cadherin showed a high level of expression in the tumors formed by the 
DU145 parental cell line (A), however only small areas of faint, irregular expression could be 
detected in EcadKD9 tumors (B). Strong expression of DSG2 could be detected in both the 







 Chapter III.4 
 
In Vivo Analysis of Cell-Cell Adhesion in Extravasation and Metastatic 
Tumor Colony Formation 
 Having examined the effects of the loss of E-cadherin based adherens 
junctions on tumorigenesis, I next sought to determine the effects of this loss on 
metastatic tumor colony formation in vivo. Given that the loss of E-cadherin 
results in a significant impairment of the formation of primary tumors, I 
hypothesized that this loss of E-cadherin would similarly lead to an impairment of 
the formation of metastatic tumor colonies. While cells lacking the expression of 
E-cadherin may be able to undergo extravasation at a rate similar to that of E-
cadherin expressing cells, I predicted that ultimately the inability to re-establish 
E-cadherin based adherens junctions would result in either a lack of metastatic 
tumor colony formation, or a significant reduction in the size of the tumor colonies 
formed.  
 To examine this hypothesis I performed an in vivo extravasation and 
metastasis assay. In this assay, cells from the parental DU145 cell line and 
EcadKD9 were injected into the lateral tail vein of age matched male 
immunodeficient NOD/SCID mice. The assay was allowed to continue for eight 
weeks at which point the mice were sacrificed and their lungs were collected, 
fixed in formalin, and embedded in paraffin. The formalin fixed paraffin 
embedded (FFPE) lungs were then cut into 5µm sections — each section 




Metastatic tumor colonies were counted in six H&E sections per animal. To 
account for extravasation, intravascular metastatic tumor colonies were not 
counted (Figure 7A); only metastatic tumor colonies found in the lung 
parenchyma were counted (Figure 7B, 7D). Two separate trials of the in vivo 
extravasation and metastasis assay were performed, and the combined results 
from these assays are discussed.  
 Interestingly, the amount of animals that developed metastatic tumor 
colonies was significantly less for those injected with the EcadKD9 cell line (40%) 
as compared to those injected with the parental DU145 cell line (92%) (Figure 
7F). While the number of tumors formed in animals that were positive for the 
formation of metastatic tumor colonies did not differ significantly between animals 
injected with the EcadKD9 cell line or the DU145 parental cell line, there was a 
striking difference in the size of the tumors formed (Figure 7B-7F). Animals 
injected with the EcadKD9 cell line developed many small metastatic tumor 
colonies (Figure 7D, 7E, 7F) — some comprised of no more than ten cells — 
while those injected with the DU145 parental cell line developed much larger 
metastatic tumor colonies (Figure 7B, 7C, 7F). To provide perspective on the size 
differential between the tumors formed in animals injected with the EcadKD9 cell 
line versus those injected with the parental DU145 cell line, one representative 
slide from each positive case was scored for tumors with a diameter measuring 
≥1mm. The cut-off value of 1mm was chosen because, from a histopathological 
point of view, this value served as a robust measurement for differentiating the 




the tumors scored from animals injected with the parental DU145 cell line 
measured ≥1mm, while no tumor scored in animals injected with the EcadKD9 
cell line had a diameter that measured ≥1mm (Figure 7F).  
 These results support the hypothesis that the loss of E-cadherin based 
adherens junctions results in the impaired formation of metastatic tumor colonies. 
Taken together with the results from the tumorigenesis assay, these results 
suggest that both primary and metastatic tumor colony formation is dependent 
upon the presence of E-cadherin based adherens junctions and that the 
presence of desmosomal adhesion alone is not sufficient to support extensive 





Figure 7: In vivo extravasation and metastatic tumor colony formation assay. 
Tumors which remained in the vasculature, and therefore did not undergo 
extravasation, were not counted in this assay (A). Tumors formed in the lung 
parenchyma of animals injected with the parental DU145 cell line (B, C, F) were 
large as compared to those formed in the lung parenchyma of animals injected 
with the EcadKD9 cell line (D, E, F; in figure D arrows point to tumors with the 
red arrow indicating the tumor shown in figure E). Significantly fewer animals 
injected with the EcadKD9 cell line developed metastatic tumor colonies as 
compared to those injected with the parental DU145 cell line, and these tumors 








 The conventional understanding of the relationship between adherens 
junctions and desmosomes holds that the assembly of desmosomes is preceded 
by and dependent upon the assembly of adherens junctions. In prostate cancer, 
the loss or reduction of E-cadherin expression is a common occurrence, while 
the expression of desmosomal cadherins has not been examined. Based on the 
conventional understanding of cell-cell anchoring junction assembly, I 
hypothesized that the loss of E-cadherin based adherens junctions in prostate 
cancer would result in the loss of desmosome formation. Surprisingly, my in vitro 
loss-of-function analysis in chapter III.2 revealed that the loss of E-cadherin 
expression in prostate cancer cells did not alter the expression of DSG2, 
therefore suggesting that the loss of adherens junctions in prostate cancer cells 
does not result in the reciprocal loss of desmosomes.  
 The idea that the formation of desmosomes is dependent upon the 
formation of adherens junctions is not without controversy; several studies have 
shown that the formation of desmosomes is unperturbed in tissues lacking the 
expression of E-cadherin. Conditional deletion of E-cadherin in the mouse 
epidermis and epidermal appendages results in hyperplasia and impaired 
terminal differentiation of the epidermis, as well as loss of integrity in the IRS and 
hair cuticle of the hair follicle (Tinkle et al., 2004). Interestingly, despite the 
absence of E-cadherin and a reduction in adherens junction protein expression, 




in the spinous layer of the mutant epidermis. Additionally, the formation of 
desmosomes in the hair follicles of mutant mice was detected at levels 
comparable to that of the hair follicles of their wild-type counterparts. This 
observed retention of desmosomal cadherin expression and desmosome 
formation in the epidermis and hair follicle was also observed in mice lacking the 
expression of both E-cadherin and P-cadherin in the epidermis and epidermal 
appendages (Tinkle et al., 2008). Further, the expression of desmosomal 
proteins and retained desmosome formation has been reported in E4.5 embryos 
lacking the expression of E-cadherin (Ohsugi et al., 1997). Taken together with 
the results of my loss-of-function analysis, these results suggest that while 
adherens junction assembly precedes that of desmosomes in early development 
as well as de novo anchoring junction formation, the formation of desmosomes 
does not strictly require the presence of adherens junctions.   
 With the knowledge that desmosomes are able to successfully form in the 
absence of anchoring junctions comes the question of whether the resulting 
adhesion is sufficient to support tissue integrity. The findings of Tinkle et al. 
demonstrate that the loss of E-cadherin based adhesion in the presence of 
desmosomal adhesion has differential consequences with respect to tissue 
integrity depending upon the tissue in which the loss occurred (Tinkle et al., 
2004). Extending these findings to tumorigenesis, the likelihood that the loss of 
adherens junctions would interfere with tumor formation is equal to the likelihood 




 In chapter III.3, I sought to determine the effects of the loss of E-cadherin 
based adherens junctions in the presence of DSG2 based desmosomes on 
prostate tumorigenesis. I found that the loss of E-cadherin based adherens 
junctions results in a dramatic reduction in the size of tumors formed despite the 
retention of desmosomal adhesion. These results led to the hypothesis that 
metastatic tumor colony formation would also be impaired by the loss of E-
cadherin based adherens junctions. In chapter III.4, I sought to examine this 
hypothesis utilizing an in vivo extravasation and metastatic tumor colony 
formation assay. The finding that animals injected with prostate cancer cells 
lacking the capacity to form E-cadherin based adherens junctions are able to 
form metastatic tumor colonies suggests that extravasation is not impaired by the 
loss of E-cadherin. However, the significant difference between the amount of 
animals that develop metastatic tumor colonies when injected with cells that have 
lost E-cadherin based adherens junctions as compared to those injected with 
cells that retain these junctions suggests that the loss of E-cadherin inhibits 
metastasis at the level of metastatic tumor colony formation. This idea is further 
supported by the finding that the metastatic tumor burden of animals injected with 
cells that have lost E-cadherin based adherens junctions is significantly lower 
than that of animals injected with cells that retain these junctions.  
 As the functional analysis performed in chapter III.3 and III.4 focused on a 
single EcadKD cell line with an undetectable level of E-cadherin expression, 
future directions will focus on repeating this in vivo analysis using EcadKD cell 




Given that heterogeneous E-cadherin expression is still detectable in these 
mutant cell lines at a low level, if the loss of E-cadherin does in fact impair 
prostate tumorigenesis, then an intermediate phenotype would be expected such 
that the resulting primary and metastatic tumors would be smaller in size than 
those formed by the parental cell line yet larger than those formed by the 
EcadKD9 cell line. Additionally, to verify that the observed impaired 
tumorigenesis is specific to the loss of E-cadherin expression, a rescue 
experiment will be performed in which the in vivo assays are repeated using 
EcadKD cell lines in which the expression of E-cadherin has been re-introduced. 
Moreover, to verify that the observed inhibition of primary and metastatic tumor 
formation is due to the loss of E-cadherin based adherens junctions and not the 
reciprocal loss of DSG2 based desmosomes, further immunofluorescence 
analysis of desmosomal proteins including plakoglobin and desmoplakin will be 
performed, and electron microscopy will be utilized to verify the formation of 
desmosomes in primary and metastatic tumors.  
 The findings described in this chapter shed a new light on the role of cell-
cell anchoring junctions in prostate tumorigenesis and metastatic prostate tumor 
colony formation as they suggest that adherens junctions are required for the 
formation of both primary and metastatic prostate tumors, while desmosomal 
adhesion alone is not sufficient to support extensive tumor formation. 
Interestingly, while E-cadherin is regarded as a tumor suppressor, the results of 




tumorigenesis as well as metastasis in the context of metastatic prostate tumor 
colony formation.  
 The role of E-cadherin as a tumor suppressor is supported by the 
frequently observed loss of E-cadherin in a variety of different cancers as well as 
the results of in vivo and in vitro analyses highlighting the role of E-cadherin as 
an inhibitor of invasive cancer (described in chapter I.9). The potential tumor 
promoting role of E-cadherin highlighted by this study provides a more extensive 
understanding of the dynamics of cell-cell adhesion in the progression of cancer. 
The putative role of E-cadherin as both a tumor suppressor and tumor promoter 
suggests that the loss of E-cadherin expression in cancer may need to be a 
transient event. This raises the question of how E-cadherin based adherens 
junctions are regulated in the progression of cancer. In chapter IV, I will explore 
this question by examining the role of the PI3K/AKT pathway in the regulation of 















Materials and Methods 
Mice 
 Both the in vivo tumorigenesis and in vivo extravasation and metastatic 
tumor colony formation assays were performed on 5-6 week old male 
NOD.CB17-PrkdcScid mice purchased from Jackson Laboratories (The Jackson 
Laboratories, Bar Harbor, ME, USA). Animal use and care followed institutional 
guidelines established by the Columbia University, Institutional Animal Care and 
Use Committee.  
 
Antibodies 
 The anti-E-cadherin mouse monoclonal antibody was purchased from 
Invitrogen (Carlsbad, CA, USA) and used at a dilution of 1:400 for 
immunofluorescence analysis of fresh fixed cells and OCT-embedded frozen 
tissue sections; a dilution of 1:1000 was used for Western Blot analysis. The anti-
DSG2 (DG3.10) mouse monoclonal antibody was purchased from Fitzgerald 
(Acton, MA, USA) and used at a dilution of 1:50 for immunofluorescence analysis 
of fresh fixed cells and OCT-embedded frozen tissue sections; a dilution of 1:500 
was used for Western blot analysis. The β-actin rabbit monoclonal antibody was 
purchased from Sigma-Aldrich (St. Louis, MI, USA) and used at a dilution of 





Generation of Stable E-cadherin Knockdown Cell Lines 
 A pSMP retroviral shRNAmir construct targeting E-cadherin was 
purchased from Open Biosystems (Thermo Fisher Scientific, Huntsville, AL, 
USA). One day prior to transfection, Phoenix2™-Ampho cells (Allele 
Biotechnology, San Diego, CA, USA) were plated in 10cm plates at a density of  
1 X 106 in MEM media containing 10% FBS. On the day of transfection, 12µg of 
plasmid DNA and 63µg of Arrest-In™ transfection reagent (Open 
Biosystems/Thermo Fisher Scientific, Huntsville, AL, USA) were added to cells in 
serum-free culture medium according to the manufacturer’s protocol. Two days 
after transfection, media from the target DU145 cell line was aspirated and the 
cells were infected once via a direct transfer of filtered media containing 10µg/mL 
Polybrene (Millipore, Billircia, MA, USA) from the transfected Phoenix2™-Ampho 
cells. This infection procedure was repeated twice the following day. The day 
after the final infection, cells were collected via trypsinization and split into 96-
well plates. The culture media (MEM with 10% FBS) was changed two days after 
plating, and fresh media containing 2 µg/mL puromycin (Invitrogen, Carlsbad, 
CA, USA) was added for selection. Surviving cell lines were maintained under 
selective conditions and used for further analysis.   
 
RNA and Protein Isolation 
 RNA isolation was conducted as described in chapter II.5. To isolate 
protein, cells were washed twice in 1XPBS. 200µL RIPA buffer (50mM Tris-HCl, 




containing a protease inhibitor cocktail (Complete, EDTA-free, Roche 
Diagnostics, Indianapolis, IN, USA) was added to cells on ice. Cells were then 
scraped using a rubber policeman and collected in an eppendorf tube. Cells were 
kept on ice for 1 hour, and vortexed for 10sec every 5 minutes. Cells were then 
centrifuged at 14,000rpm for 10 min at 4ºC, and the protein lysate was 
transferred to a new eppendorf tube. Protein concentration was determined using 
the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA).    
 
qRT-PCR 
 qRT-PCR was conducted as described in chapter II.5. Primers used for 
qRT-PCR analysis are shown in Table 1. 
 
Table 1: RT-PCR Primers and qRT-PCR Primers 
qRT-PCR Primers 
Transcript Forward Primer Reverse Primer 
E-cadherin* 5-’CAGCACGTACACAGCCCTAA-3’ 5’-ACCTGAGGCTTTGGATTCCT-3’ 
DSG2 5’-ATCAATGCAACAGATGCAGATGA-3’ 5’-TGTCAAAGTGTAGCTGCTGTGT-3’ 
β-actin  5’-AAACTGGAACGGTGAAGGTG-3’ 5’-GTGGCTTTTAGGATGGCAAG-3’ 
*E-cadherin primers designed as reported by Chen et al., 2010.  
 
Immunofluorescence Analysis 






Western Blot Analysis 
 Western Blot analysis was performed by adding 4X SDS Sample Buffer 
(Novagen, San Diego, CA, USA) to 35µg of protein lysate isolated from the cell 
lines of interest. Samples were boiled for 5 min and separated by 4%-20% Tris-
HCl SDS-PAGE. Gel transfer to a nitrocellulose membrane was conducted using 
the iBlot® gel transfer system (Invitrogen, Carlsbad, CA, USA) following the 
manufacturer’s protocol. Membranes were blocked in 5% nonfat milk/1X TBST 
for one hour with constant agitation. Membranes were incubated overnight at 4ºC 
in 5% nonfat milk/1X TBST containing the primary antibody of interest with 
constant agitation. Membranes were washed three times for 5 min in 1X TBST 
with constant agitation. Membranes were incubated in 5% nonfat milk/1X TBST 
containing a 1:2000 dilution of either anti-mouse or anti-rabbit HRP conjugated 
secondary antibody (GE Healthcare, Little Chalfont Buckinghamshire, UK) with 
constant agitation. Samples were treated with ECL Plus Western Blotting 
Detection reagent (GE Healthcare, Little Chalfont Buckinghamshire, UK) for 1 
min and visualized on Amersham Hyperfilm™ ECL (GE Healthcare, Little 
Chalfont Buckinghamshire, UK).  
  
In vivo Tumorigenesis Assay 
 Cell lines of interest were trypsinized, pelleted, and counted. Following 
counting, 100µL of 1X106 cells in MEM with 10% FBS were combined with 100µL 
of Matrigel™ (BD Biosciences, Franklin Lakes, NJ, USA) on ice.  Age-matched 




of the 1:1 cell-Matrigel suspension. Tumors were allowed to form for 8 weeks at 
which point the animals were sacrificed. Tumors were collected and tumor 
volume was assessed via caliper measurement. Tumors were then dissected, 
embedded in O.C.T. Compound (Sakura Finetek, Torrance, CA, USA), snap 
frozen, and 5µm sections were made for immunofluorescence analysis. Two 
separate trials of the assay were performed.   
 
In vivo Extravasation and Metastatic Tumor Colony Formation  
 Cell lines of interest were trypsinized, pelleted, washed in 1X PBS, and 
counted. Following counting, 100µL of 1X106 cells in 1X PBS were injected into 
the lateral tail vein of age matched male immunodeficient NOD/SCID mice with 
the kind assistance of Magda Stumpfova, a graduate student in the laboratory of 
Dr. David Owens. Two separate trials of the assay were performed. Animals 
were sacrificed eight weeks after the injection and their lungs were collected, 
formalin fixed, and paraffin embedded. Six 5µm tissue sections were cut from 
each FFPE block and the sections were stained with H&E. Each 5µm section 
was separated by 100µm to minimize overlap in tumor counting. Tumors in each 
H&E section were counted with kind assistance from Mireia Castillo-Martin, a 
pathologist in the laboratory. Tumors found exclusively in one tissue section were 
counted, while tumors found in multiple sections were only counted as present in 







 Experimental data is expressed as mean ± standard deviation; statistical 
analysis was performed using a Student’s t-test. Fisher’s exact test was used for 
the analysis of categorical data. Values were considered statistically significant at 





























Functional Analysis of the Regulation of Cell-Cell Adhesion by PI3K/AKT 





















 As demonstrated in chapter III, the permanent loss of E-cadherin 
expression in prostate cancer results in impaired tumorigenesis and metastatic 
tumor colony formation. While the role of E-cadherin in cancer has been well 
established as that of a tumor suppressor, the findings of this study suggest an 
additional role for E-cadherin as a tumor promoter in specific stages of prostate 
cancer progression. The duality of this role intimates the need for a transient 
means of E-cadherin repression in prostate cancer. One such mechanism by 
which E-cadherin may be transiently repressed in cancer is via EMT, as 
hallmarks of EMT include reversibility and the downregulation of E-cadherin. As 
described in chapter I.11, the expression of Snail has been associated with the 
downregulation of E-cadherin in breast and colorectal cancer while the 
transcriptional repression of E-cadherin via Snail has been demonstrated in a 
variety of cancer cell lines in vitro (Blanco et al., 2002; Cheng et al., 2001; Pena 
et al., 2005; Cano et al., 2000; Batlle et al., 2000). This Snail mediated EMT-like 
transcriptional repression of E-cadherin in cancer may be regulated by the 
PI3K/AKT signaling pathway. As described in chapter I.13, in vitro analysis of 
breast cancer cell lines has demonstrated that AKT is able to promote an EMT-
like phenotype, while analysis of squamous cell carcinoma cell lines has shown 
that overexpression of activated AKT results in the downregulation of E-cadherin 




of E-cadherin in the presence of activated AKT was concomitant with the 
upregulation of Snail, and AKT activity has also been shown to stabilize Snail via 
the repression of the Snail inhibitor GSK3β (Grille et al., 2003; Zhou et al., 2004). 
The PI3K/AKT signaling pathway is known to be central to the progression of 
prostate cancer. As described in chapter I.12, in vivo analysis of mouse models 
of prostate cancer — such as the heterozygous Pten+/- knock out mouse model, 
the Nkx3.1;Pten compound mutant mouse model, and the transgenic MPAKT 
mutant mouse model — demonstrate that the aberrant activation of the 
PI3K/AKT pathway results in the formation of PIN and invasive prostatic 
carcinoma lesions (Di Cristofano, 1998; Di Cristofano 2001; Kim et al., 2002; 
Abate-Shen et al., 2003; Majumder et al., 2003). The potential requirement for 
transient repression of E-cadherin in the progression of prostate cancer coupled 
with the demonstrated significance of PI3K/AKT signaling in the progression of 
prostate cancer and the association of this signaling with EMT-like events in 
several other types of cancer, led me to hypothesize that PI3K/AKT signaling 
may lead to the EMT-like transcriptional repression of E-cadherin via Snail in 
prostate cancer.      
 To investigate this hypothesis I sought to examine the effects of activated 
PI3K/AKT signaling on E-cadherin expression in a prostate cancer environment. I 
again chose to utilize the DU145 human metastatic prostate cancer cell line as 
the representative prostate cancer environment for this portion of the study, as 
this cell line reportedly contains an intact PI3K/AKT signaling pathway insofar as 




under normal cell culture conditions (Grunwald et al., 2002). In chapter IV.2 I 
stably expressed a construct containing constitutively active AKT in the DU145 
cell line, and examined the effects of AKT activity on the expression of E-
cadherin and DSG2. I found that activated AKT expression results in a significant 
reduction in the expression of E-cadherin, while the expression of DSG2 was 
relatively unaffected in vitro. In chapter IV.3 I examined the effects of activated 
AKT expression on the expression of Snail and found that there was a dramatic 
increase in the nuclear accumulation of Snail, indicative of increased Snail 
activity.   
 I next sought to examine the effects of activated AKT and E-cadherin 
inhibition on tumorigenesis. In chapter IV.4 I performed an in vivo tumorigenesis 
assay in NOD/SCID mice by injecting my cell lines of interest subcutaneously, 
allowing for tumor formation, and subsequently analyzing the resulting tumors for 
the expression of E-cadherin, DSG2, pAKT and Snail. Interestingly, the tumors 
formed by the activated AKT expressing cells were significantly smaller than 
those formed by the parental DU145 cell line; however they were unexpectedly 
positive for the expression of E-cadherin as well as DSG2. Further analysis 
revealed that there appears to be an inverse correlation between the expression 
of E-cadherin and that of pAKT, such that areas of the tumor with high levels of 
AKT expression generally showed low or no expression of E-cadherin. This 
inverse correlation could also be observed for the expression of Snail versus the 




 Lastly, I sought to examine the effects of activated AKT on extravasation 
and metastatic tumor colony formation. In chapter IV.5, I performed an in vivo 
metastasis assay by injecting my cell lines of interest into the lateral tail vein of 
NOD/SCID mice, allowing for tumor formation, and subsequently analyzing the 
lungs of the injected animals for the formation of metastatic tumor colonies.  
Interestingly, there was a significant decrease in the amount of animals that 
formed metastatic tumor colonies as well as the amount tumors formed in 
positive cases for animals injected with activated AKT expressing cells. In 
chapter IV.6, I describe the relationship between activated AKT mediated 
signaling, Snail, and E-cadherin in vitro as well as the effects of activated AKT on 
Snail and E-cadherin in tumorigenesis, extravasation, and metastatic tumor 
colony formation in vivo. The relationship between activated AKT mediated 
signaling, Snail, and DSG2 is also discussed. The methods utilized for this 




In Vitro Analysis of Anchoring Junctions and Activated AKT Signaling 
 The first goal of this study was to test the hypothesis that PI3K/AKT 
signaling may lead to an EMT-like transcriptional repression of E-cadherin via the 
transcription factor Snail in prostate cancer. To accomplish this goal I wanted to 
activate the PI3K/AKT signaling pathway in a prostate cancer environment and 




To activate the PI3K/AKT signaling pathway I chose to overexpress a construct 
containing a myristoylated form of AKT that is HA-tagged (hereafter referred to 
as MAH). The myristoylation of AKT targets AKT to the cell membrane resulting 
in its constitutive activation (Kohn et al., 1996). Therefore the overexpression of 
MAH in the DU145 cell line results in the constitutive activation of the PI3K/AKT 
signaling pathway as a result of the constitutive activation of AKT.  
 DU145 cells were infected with an MAH retroviral construct and grown 
under selective conditions. The resulting stable mutant DU145 cell lines 
(hereafter referred to as MAH cell lines) were then screened for the expression of 
MAH via its HA-tag using immunofluorescence analysis. MAH cell line 6 
(hereafter referred  to as MAH6) displayed a relatively high and homogeneous 
level of MAH expression (Figure 1A); while MAH cell line 7 (hereafter referred to 
as MAH7) also displayed a relatively high level of MAH expression, however this 








Figure 1: Immunofluorescence analysis to screen for the expression of Myr-AKT-HA in DU145 
cell lines stably transfected with the MAH construct. MAH6 (A) shows a high and homogeneous 
level of MAH expression, while MAH7 (B) shows a heterogeneous mix of cells showing either 
high levels of MAH expression or no MAH expression.   
 
 
 I next examined the effects of AKT activity on E-cadherin expression in the 
MAH cell lines via qRT-PCR (Figure 2). Interestingly, the expression of E-
cadherin was reduced in both of the MAH cell lines analyzed, however only 
MAH6 showed a significant reduction (93%) in the expression of E-cadherin. I 
then examined the expression of E-cadherin at the protein level in the MAH cell 
lines using immunofluorescence analysis. Consistent with the qRT-PCR results, 
the expression of E-cadherin was dramatically reduced and effectively 
undetectable at the cell border in MAH6 (Figure 3B, 3C, 3D). However E-
cadherin expression could be detected at the cell border in MAH7, though this 




expression (Figure 3E, 3F). These results show that the expression of E-cadherin 
is most dramatically reduced in the presence of a homogeneously high level of 
activated AKT expression, which supports the hypothesis that AKT mediated 
signaling results in the transcriptional repression of E-cadherin in prostate 
cancer.  
 
Figure 2: qRT-PCR analysis of E-cadherin mRNA expression in the MAH cell lines. MAH6 
shows a significant reduction (93%) of E-cadherin expression, while MAH7 shows a modest 
reduction (18%) of E-cadherin expression. Scale bars represent standard deviation; (**) 





Figure 3: Immunofluorescence and Western blot analysis of E-cadherin 
expression in MAH cell lines. The expression of E-cadherin is dramatically 
reduced in MAH6 and is effectively undetectable at the cell border (B, C, D). 
The expression of E-cadherin is detectable at the cell border of MAH7, 
however this expression is low or absent in cells expressing a high level of 




 As mentioned in chapter I.13 a study conducted by Grille et al. found that 
overexpression of activated AKT in a squamous cell carcinoma cell line results in 
reduced E-cadherin mRNA expression (Grille et al., 2003). This study also 
showed that there was a mislocalization of desmoplakin in the presence of 
activated AKT expression, such that desmoplakin displayed granular staining in 
the cytoplasm and failed to localize to the cell-cell border. This mislocalization of 
desmoplakin is indicative of a failure of desmosome formation, thereby 
suggesting that activated AKT mediated signaling may influence the formation of 
desmosomes. To examine the possibility that activated AKT may result in the 
transcriptional repression of DSG2, I examined the expression of DSG2 via qRT-
PCR in the MAH cell lines. Interestingly, I found that the expression of DSG2 
varied in the mutant cell lines examined. There was a small but significant 
increase (1.6X) in the expression of DSG2 in MAH6, while there was a significant 
decrease (56%) in the expression of DSG2 in MAH7 (Figure 4). These results 
may reflect that the level of DSG2 in the MAH cell lines is arbitrary, suggesting 
that the expression of DSG2 is not affected by activated AKT expression. 
Alternatively, these results may suggest that the expression of DSG2 is affected 
by activated AKT expression; however this effect is negated in cases where E-






Figure 4: qRT-PCR analysis of DSG2 mRNA expression in the MAH cell lines. There is a 
small but significant increase (1.6X) of DSG2 expression in MAH6, while a significant 
decrease (56%) of DSG2 expression is detected in MAH7. Scale bars represent standard 




 I then analyzed the expression of DSG2 at the protein level in the MAH 
cell lines using immunofluorescence analysis. The expression of DSG2 could be 
detected at the cell border of both MAH6 and MAH7 cells (Figure 5C-5F). 
Consistent with the qRT-PCR results, Western blot analysis shows that there is a 




line. Interestingly, despite this higher level of DSG2 protein expression, cell 
border localization of DSG2 is detected in fewer cells of the MAH6 cell line as 
compared to the DU145 parental cell line. In general, DSG2 cell border 
expression could be detected in cells expressing a high level of activated AKT, 
however activated AKT expressing cells in which DSG2 expression is either low 
or absent were detected on occasion. This pattern of DSG2 expression may 
signify that the effect of activated AKT mediated signaling on DSG2 expression is 







Figure 5: Immunofluorescence and Western blot analysis of DSG2 expression in the MAH cell 
lines. The level of DSG2 protein expression in MAH6 cells is greater than that of the parental 
DU145 cell line (B). DSG2 expression can be detected at the cell border of MAH6 (C, D) and 













In Vitro Analysis of EMT and Adherens Junctions 
 Having found that the expression of activated AKT results in decreased E-
cadherin expression at the mRNA level, I next sought to examine the possibility 
that this transcriptional repression of E-cadherin may be mediated by Snail. As 
the expression of E-cadherin was most significantly reduced in MAH6, I chose to 
move forward with the analysis of this particular cell line for the remainder of the 
study. I first analyzed the expression of Snail in MAH6 cells utilizing qRT-PCR, 
and found that there was a small but significant increase (1.8X) in the expression 
of Snail in this cell line (Figure 6). I then utilized immunofluorescence analysis to 
examine the expression of Snail at the protein level. Interestingly, there was a 
dramatic increase in the nuclear localization of Snail in the MAH6 cell line as 
compared to the parental DU145 cell line (Figure 7). While nuclear localization of 
Snail can be detected in the parental DU145 cell line, this expression is very low 
and is difficult to detect above background fluorescence (Figure 7A, 7B). 
However, the expression of Snail in MAH6 cells is robust and readily detectable 
in the nucleus (Figure 7C, 7D).  
 As described in chapter I.11, the expression of the EMT-associated 
transcription factor Slug has also been associated with reduced E-cadherin 
expression in esophageal squamous cell carcinoma (Uchikado et al., 2005). 
Additionally, Slug has been shown to bind E-box elements in the E-cadherin 




lines as well as in the MDCK cell line (Hajra et al., 2002; Bolos et al., 2002). 
PI3K/AKT signaling has been associated the stabilization of Slug via the indirect 
activation of β-catenin (Saegusa et al., 2009). The expression of the EMT-
associated transcription factor Twist has also been shown to be associated with 
the loss of E-cadherin in invasive lobular carcinoma, and the expression of 
exogenous Twist has been shown to inhibit E-cadherin expression in vitro (Yang 
et al., 2004). Twist has been shown to be a direct target of AKT phosphorylation, 
and this phosphorylation has been found to have a positive effect on Twist 
activity (Vichalkovski et al., 2010). Given that Slug and Twist are known 
transcriptional repressors of E-cadherin, and that their activity has been 
associated with PI3K/AKT signaling, I wanted to examine the expression of Slug 
and Twist in MAH6 cells to determine if there was an increase in the nuclear 
accumulation of these transcription factors in addition to Snail. I therefore 
examined the expression of Slug and Twist in MAH6 cells via 
immunofluorescence and found that no increase in nuclear accumulation could 
be detected for either Slug (Figure 8) or Twist (Figure 9) in MAH6 cells as 
compared to the DU145 parental cell line. Interestingly, while the nuclear 
expression of both Slug and Twist could be detected in the parental DU145 cell 
line (Figure 8A, 8B, 9A, 9B), this expression appears to be lost in MAH6 cells 
where only a low level of diffuse cytoplasmic Twist expression can be detected 
(Figure 8C, 8D, 9C, 9D). Taken together these results suggest that activated 
AKT expression results in the nuclear accumulation of Snail and the 




of E-cadherin may be a result of Snail activity, but is not a result of the activity of 
Slug or Twist.  
  
 
Figure 6: qRT-PCR analysis of Snail mRNA expression in MAH6 cells. There is a slight but 
significant increase in the expression of Snail in MAH6 cells. Scale bars represent standard 










Figure 7: Immunofluorescence analysis of Snail expression in MAH6 cells. There is a high level 
of nuclear Snail expression in MAH6 cells (C, D) as compared to the DU145 parental cell line 
(A, B). This nuclear localization is indicative of Snail activity. The level of Snail expression is 
relatively equal in MAH6 cells and the DU145 parental cell line (E). (Snail is labeled in red, and 






Figure 8: Immunofluorescence analysis of Slug expression in MAH6 cells. Expression of Slug can 
be detected in the nuclei of the DU145 parental cell line (A, B), however only a low level of diffuse 
cytoplasmic Slug expression can be detected in MAH6 cells (C, D) which is indicative of Slug 







Figure 9: Immunofluorescence analysis of Twist expression in MAH6 cells. Expression of Twist 
can be detected in the nuclei of the DU145 parental cell line (A, B), however only a low level of 
diffuse cytoplasmic Twist expression can be detected in MAH6 cells (C, D) which is indicative of 




In Vivo Tumorigenesis Analysis of Cell-Cell Adhesion in Prostate Cancer 
 Having found that the expression of activated AKT results in the 
transcriptional repression of E-cadherin as a possible consequence of Snail 
activity, I next sought to examine the effects of activated AKT mediated signaling 
on tumorigenesis in vivo. Given that in chapter III.3 I found that the loss of E-
cadherin expression results in impaired tumorigenesis, I hypothesized that a high 




due to the observed transcriptional repression of E-cadherin. To test this 
hypothesis I performed an in vivo tumorigenesis assay in which MAH6 cells and 
cells from the parental DU145 cell line were injected subcutaneously into the 
backs of age-matched male immunodeficient NOD/SCID mice. Tumors were 
then allowed to grow for eight weeks at which point the mice were sacrificed and 
the tumors were collected for analysis. Two separate trials of the in vivo 
tumorigenesis assay were performed, and the combined results from these 
assays are discussed. 
 Interestingly, much like the tumors formed by E-cadherin knockdown cells, 
there was a notable difference in the size of the tumors formed by MAH6 cells as 
compared to those formed by the parental DU145 cell line. The tumors formed by 
the DU145 parental cell line (Figure 10A, black arrow; 10B, left); were large (1.33 
cm3 ± 0.71) while the tumors formed by MAH6 cells (Figure 10A, red arrow; 10B, 
right) were significantly smaller by comparison (0.36 cm3 ± 0.27; P = 0.0001). 
However, it should be noted that these MAH6 tumors, though small, were 
significantly larger (P = 0.001) than those formed by the EcadKD9 cell line (0.04 









Figure 10: In vivo tumorigenesis assay. Cells from the DU145 parental cell line (A, black 
arrow) and MAH6 cells (A, red arrow) were injected subcutaneously in NOD/SCID mice. The 
DU145 parental cell line produced large tumors (B, tumor shown on the left; C) while MAH6 
cells produced tumors that were significantly smaller (B, tumor shown on the right, C). Scale 







 Frozen OCT embedded sections of the tumors were then analyzed for the 
expression of E-cadherin and DSG2 via immunofluorescence to ensure that the 
cadherin expression profile observed in vitro was maintained in the tumors 
formed in vivo. As expected, the expression of DSG2 could be detected at the 
cell border of tumors formed by both MAH6 cells and the parental DU145 cell line 
(Figure 11C, 11D). Surprisingly, E-cadherin expression was also detected at the 
cell border of tumors formed by both the DU145 parental cell line and the MAH6 
cells (Figure 11A, 11B).   
 To determine whether this unexpected E-cadherin expression was a result 
of the loss of MAH expression in the MAH6 tumors I performed co-
immunofluorescence analysis for the expression of the HA-tagged myristoylated 
AKT and E-cadherin in MAH6 tumors. The results of this analysis show that MAH 
expression was retained in the MAH6 tumors, therefore the unexpected 
expression of E-cadherin was not due to the expansion of drug resistant cells 
lacking the expression of the MAH construct (Figure 12). Co-labeling analysis 
further revealed that the expression of E-cadherin appears to be inversely 
proportional to the expression of MAH, such that cells with a high level of MAH 
expression display a low level of E-cadherin expression while cells with a low 
level of MAH expression display a high level of E-cadherin expression (Figure 
12A-C). Interestingly, further co-immunofluorescence analysis showed that this 
pattern of expression could also be detected for MAH and DSG2, though to a 




with a high level of MAH expression, DSG2 expression was often more robust in 
cells with low or no MAH expression.  
 
Figure 11: Immunofluorescence analysis of tumors formed by the DU145 parental cell line (A, C) 
and MAH6 cells (B, D). E-cadherin showed a high level of expression in the tumors formed by 
both the DU145 parental cell line (A) and MAH6 cells (B). Strong expression of DSG2 could also 





Figure 12: Co-immunofluorescence analysis of E-cadherin and MAH, and DSG2 and MAH in 
tumors formed by MAH6 cells. E-cadherin and DSG2 are shown in green. An anti-HA-tag 
antibody was used to detect the expression of MAH, shown in red. Nuclei are labeled with DAPI, 
shown in blue. The expression of E-cadherin appears to be inversely proportional to that of MAH 
(A-C). The expression of DSG2 also appears to be inversely proportional to MAH (D-F), though to 











 I next sought to determine whether the same inverse proportionality could 
be detected for Snail expression and E-cadherin expression. To accomplish this 
goal I examined the expression of Snail and E-cadherin via co-
immunofluorescence analysis in tumors formed by MAH6 cells and the DU145 
parental cell line. Interestingly, nuclear Snail expression could be detected in 
tumors formed by MAH6 cells, however this expression was generally not as 
robust as that observed in vitro (Figure 13F-H). Despite this fact, areas of MAH6 
tumors that showed the highest levels of nuclear Snail expression often showed 
low or no expression of E-cadherin, while E-cadherin expression was often most 
robust in areas with low or no nuclear Snail expression. Interestingly, this pattern 
of expression was also detected in tumors formed by the parental DU145 cell line 
(Figure 13C-E). While the nuclear expression of Snail in the parental DU145 cell 
line was very low in vitro, areas of relatively high nuclear Snail expression could 
be detected in vivo. As in the tumors formed by MAH6 cells, the expression of 
Snail often appears to be inversely proportional to that of E-cadherin in the 
tumors formed by the DU145 parental cells. Given that the expression of 
activated AKT is not detected in the parental DU145 cell line in vitro, I asked 
whether the unexpectedly high level of nuclear Snail expression in the tumors 
formed by the DU145 parental cell line in vivo could be explained by 
unanticipated activated AKT expression in these tumors. Immunofluorescence 
analysis revealed that high levels of cytoplasmic pAKT (i.e. activated AKT) 
expression could be detected in certain areas of the tumors formed by the 




pAKT expression and Snail expression could not be performed due to antibody 
incompatibility, the correlation between pAKT expression and Snail expression in 
tumors formed by both the parental DU145 cell line and MAH6 cells illustrates 
the possibility that nuclear Snail expression is a result of AKT mediated signaling.  
 Taken together the results of this in vivo tumorigenesis assay show that 
the tumors formed by MAH6 cells are significantly smaller than those formed by 
the DU145 parental cell line. Unexpectedly, the expression of E-cadherin can be 
detected in tumors formed by both MAH6 cells and the DU145 parental cell line. 
This observation coupled with the comparatively small size of MAH6 tumors 
suggests that tumorigenesis favors the expression of E-cadherin, thereby raising 
the possibility that the reduced size of MAH6 tumors may be a reflection of the 
selection and expansion of a rare population of MAH6 cells with retained E-
cadherin expression. Further, this E-cadherin expression appears to be inversely 
proportional to both activated AKT expression and Snail expression. This result 
supports the hypothesis that PI3K/AKT signaling may lead to an EMT-like 
transcriptional repression of E-cadherin via the transcription factor Snail in 
prostate cancer while suggesting that the extent of this transcriptional repression 
may be dependent upon the level of PI3K/AKT signaling and/or Snail activity. 
Additionally, DSG2 expression is retained in both MAH6 tumors and tumors 
formed by the DU145 parental cell line. This DSG2 expression appears to be 
inversely proportional to activated AKT expression, however to a lesser degree 




may influence DSG2 expression, though to a lesser degree than that of E-







Figure 13:  Immunofluorescence analysis of pAKT in tumors formed by MAH6 cells and the 
DU145 parental cell line (A-B). pAKT expression can be detected in tumors formed by both 
the DU145 parental cell line (A) and MAH6 cells (B). Co-immunofluorescence analysis of E-
cadherin and Snail in tumors formed by the DU145 parental cell line and MAH6 cells (C-H). 
The expression of E-cadherin appears to be inversely proportional to that of Snail in tumors 
formed by both the DU145 parental cell line (C-E) and MAH6 cells (F-H).  E-cadherin is 
shown in green. pAKT is shown in red. Snail is also shown in red. Nuclei are labeled with 







In Vivo Analysis of Cell-Cell Adhesion in Extravasation and Metastatic 
Tumor Colony Formation 
 Having examined the effects of activated AKT mediated signaling on 
tumorigenesis, I next sought to determine the effects of this AKT mediated 
signaling on metastatic tumor colony formation in vivo. The results of the in vivo 
tumorigenesis assay in chapter IV.4 revealed that MAH6 tumors were 
unexpectedly positive for the expression of E-cadherin, yet the tumors formed in 
animals injected with MAH6 cells were significantly smaller that those formed in 
animals injected with the parental DU145 cell line. Given the observed inverse 
proportionality of activated AKT expression and E-cadherin expression in vivo, 
coupled with the observation that most MAH6 cells have a very high level of 
activated AKT expression in vitro, this size discrepancy may be explained by the 
selection and expansion of a rare population of MAH6 cells that have retained E-
cadherin expression as a result of a low level of activated AKT expression. I 
therefore hypothesized that metastatic tumor colony formation would be impaired 
in animals injected with MAH6 cells as compared to those injected with the 
DU145 parental cell line, as only a rare population of MAH6 cells expressing a 
low level of activated AKT would be expected to retain the E-cadherin expression 




 To examine this hypothesis I performed an in vivo extravasation and 
metastasis assay. In this assay, MAH6 cells and cells from the parental DU145 
cell line were injected into the lateral tail vein of age-matched male 
immunodeficient NOD/SCID mice. The assay was allowed to continue for eight 
weeks at which point the mice were sacrificed and their lungs were collected, 
fixed in formalin, and embedded in paraffin. The formalin fixed paraffin 
embedded (FFPE) lungs were then cut into 5µm sections — each section 
separated by 100µm — and stained with hematoxylin and eosin (H&E). 
Metastatic tumor colonies were counted in six H&E sections per animal. To 
account for extravasation, intravascular metastatic tumor colonies were not 
counted; only metastatic tumor colonies found in the lung parenchyma were 
counted (Figure 14A, 14C). Two separate trials of the in vivo extravasation and 
metastasis assay were performed, and the combined results from these assays 
are discussed.  
 Interestingly, significantly fewer animals injected with MAH6 cells 
developed metastatic tumor colonies (24%) as compared to those injected with 
the parental DU145 cell line (92%) (Figure 14E). Additionally, significantly fewer 
tumors formed in the animals that were injected with MAH6 cells and were 
positive for the formation of metastatic tumor colonies (0.7 ± 2.4) as compared to 
animals injected with the DU145 parental cell line (9.3 ± 8.9) (Figure 14E). 
Moreover, the tumors that were able to form in animals injected with MAH6 cells 
were generally smaller than those injected with the parental DU145 cell line 




from animals injected with MAH6 cells measured ≥1mm, while 44% of the tumors 
scored in animals injected with the parental DU145 cell line had a diameter that 
measured ≥1mm. These results support the idea that only a rare population of 
MAH6 cells retains the capacity to form metastatic tumor colonies, as the time 
required for the selection and expansion of this population would be expected to 
delay tumor formation. This delay in tumor formation would be expected to   
result in the formation of fewer tumors overall that are smaller in size than those 
formed by cells that did not have to undergo this same delay.  
 It must be noted that, though small, the metastatic tumor colonies formed 
in animals injected with MAH6 cells were consistently larger than those formed in 
animals injected with EcadKD9 cells, based on observation. The finding in 
chapter III that EcadKD9 cells have lost E-cadherin expression both in vitro and 
in vivo suggests that EcadKD9 cells are relatively homogeneous with respect to 
the loss of E-cadherin expression. Therefore the selection and expansion of a 
rare E-cadherin negative cell population resulting in the formation of the 
observed E-cadherin negative tumors in chapter III.3 would not be expected to 
have occurred for these cells. As a result, the time allowed for metastatic tumor 
colony formation by EcadKD9 cells would be effectively longer than that for the 
putative rare population of E-cadherin positive MAH6 cells. With this in mind, the 
observation that tumors formed in animals injected with MAH6 cells are actually 
larger than those formed in animals injected with EcadKD9 cells, despite the 
possibility that these MAH6 tumors had less time to form, supports the idea that 




cadherin as E-cadherin positive tumors have been found to be consistently larger 
than E-cadherin negative tumors in chapter III of this study. Additionally, the 
finding that the MAH6 tumors formed in the in vivo tumorigenesis assay 
described in chapter IV.4 were consistently positive for E-cadherin expression 
supports the idea that the metastatic tumor colonies formed by MAH6 cells retain 
the expression of E-cadherin. 
 In summary, the results of this in vivo extravasation and metastatic tumor 
colony formation assay support the prediction that metastatic tumor colony 
formation would be impaired in animals injected with MAH6 cells as compared to 
those injected with the DU145 parental cell line. Further, the observed 
impairment of metastatic tumor colony formation by MAH6 cells may be 
attributable to the selection and expansion of a rare population of E-cadherin 









Figure 14: In vivo extravasation and metastatic tumor colony formation assay. Tumors formed in 
the lung parenchyma of animals injected with the parental DU145 cell line (A, B, E) were large as 
compared to those formed in the lung parenchyma of animals injected with MAH6 cells (C, D, E). 
Significantly fewer animals injected with EcadKD9 cells developed metastatic tumor colonies as 











 The role of E-cadherin as a tumor suppressor is well established. As 
described in chapter I.9, the loss of E-cadherin expression has been associated 
with many types of cancer, and the role of E-cadherin in the inhibition of tumor 
cell invasion has been extensively examined both in vitro and in vivo. However, 
there are exceptions to this rule, as the rare up-regulation or overexpression of 
E-cadherin has been documented in ovarian cancer and inflammatory breast 
cancer (Sundfeldt et al., 1997; Kleer et al., 2001). These exceptions suggest that 
while E-cadherin has clearly been shown to play a role in the inhibition of cancer 
cell invasion, the function of E-cadherin may also be advantageous at certain 
stages of cancer progression. As demonstrated in chapter III, the loss of E-
cadherin impairs the formation of primary and metastatic prostate tumors in vivo, 
suggesting that the presence of E-cadherin based adherens junctions may be 
required for extensive tumor formation.  
 Given the possibility that E-cadherin may play both a positive and negative 
role in the progression of prostate cancer, flexibility in the regulation of E-
cadherin expression could be distinctly advantageous in the progression of 
prostate cancer. While the permanent loss of E-cadherin via such mechanisms 
as LOH coupled with inactivating mutations has been documented in gastric 
cancer and lobular breast carcinoma, the loss of E-cadherin expression in cancer 




silencing, transcriptional repression, or post-transcriptional modifications (Becker 
et al., 1994; Berx 1995; Yoshiura et al., 1995; Kanazawa et al., 2002; Johnson et 
al., 2007). In this chapter I wished to examine the transcriptional regulation of E-
cadherin as a possible form of transient E-cadherin repression, focusing on the 
as yet unexplored relationship between the PI3K/AKT signaling pathway and the 
EMT-like repression of E-cadherin in prostate cancer. As described in the 
overview of this chapter, the demonstrated significance of PI3K/AKT signaling in 
the progression of prostate cancer and the association of this signaling with 
EMT-like events in several other types of cancer, led me to hypothesize that 
PI3K/AKT signaling may lead to the EMT-like transcriptional repression of E-
cadherin via Snail in prostate cancer.      
 In chapter IV.2 I found that a homogenously high level of activated AKT 
expression was associated with the transcriptional repression of E-cadherin. 
Further, in chapter IV.3 it was demonstrated that this homogenously high level of 
activated AKT expression was also associated with the nuclear accumulation of 
Snail, indicative of Snail activity. It was also shown that this activated AKT 
expression was not associated with the nuclear accumulation of the EMT related 
transcription factors Slug and Twist. These in vitro findings strongly support the 
hypothesis that PI3K/AKT signaling leads to the transcriptional repression of E-
cadherin specifically via the activation of the EMT-related transcription factor 
Snail.  
 To verify that the observed transcriptional repression of E-cadherin is a 




analysis of E-cadherin expression in MAH6 cells treated with an inhibitor of AKT 
activity. Similarly, treatment of MAH6 cells with an AKT inhibitor will also be used 
to verify that the observed nuclear accumulation of Snail expression is a result of 
AKT activity. Treatment of MAH6 cells with an AKT inhibitor would be expected 
to result in the re-expression of E-cadherin and a loss of nuclear Snail 
accumulation. Additionally, to examine whether there is a direct interaction 
between Snail and E-cadherin, a chromatin immunoprecipitation (ChIP) assay 
will be performed to determine if Snail binds directly to the E-cadherin promoter 
in MAH6 cells at a level that is significantly greater than that observed in the 
DU145 parental cell line.  
  In chapter IV.4, in vivo tumorigenesis analysis of activated AKT 
expression in prostate cancer cells showed that tumors formed by MAH6 cells 
were significantly smaller than those formed by the DU145 parental cell line. 
Unexpectedly, both tumor types were found to express E-cadherin. This 
unexpected E-cadherin expression may be explained by the finding that, unlike 
MAH6 cells in vitro, MAH6 cell in vivo were found to express a comparatively low 
level of activated AKT. Further, this activated AKT expression was found to be 
inversely proportional to that of E-cadherin in MAH6 cells. This inverse 
proportionality of activated AKT and E-cadherin expression was also observed in 
the DU145 cell line where the expression of pAKT was detected. Moreover, the 
expression of Snail and E-cadherin was also found to be inversely proportional in 
both MAH6 cells and the DU145 parental cell line. These results suggest that the 




selection and expansion of a rare cell population expressing a level of activated 
AKT low enough to permit the expression of E-cadherin. These results further 
suggest that a high level of Snail activity is required for significant repression of 
E-cadherin expression.  
 In chapter IV.5, in vivo extravasation and metastatic tumor colony 
formation analysis showed that fewer animals injected with MAH6 cells went onto 
form tumors than those injected with the DU145 parental cell line. Additionally, 
fewer metastatic tumor colonies formed in MAH6 injected animals and these 
tumor colonies were much smaller in size as compared to those found in animals 
injected with the DU145 parental cell line. The reduced tumor colony size 
observed in this assay is consistent with the reduced tumor size observed in the 
E-cadherin positive MAH6 tumors formed in the tumorigenesis assay of chapter 
IV.4. Taken together with the reduced number of tumor colonies formed overall in 
animals injected with MAH6 cells, these results lend further support to the idea 
that the formation of tumors by MAH6 cells occurs via the selection and 
expansion of a rare, E-cadherin positive MAH6 cell population.  
 To further explore the idea that MAH6 tumors are formed as a result of the 
selection and expansion of a rare E-cadherin positive cell population, future 
directions will focus on repeating these in vivo assays using the MAH7 cell line 
which is heterogeneous for cells expressing a high level of activated AKT. Given 
that MAH7 cells contain both E-cadherin positive and E-cadherin negative cells, 
the resulting MAH7 tumors would be expected to be much larger than those 




activated AKT and a high level of E-cadherin is much less rare in the MAH7 cell 
line. Additionally, the inverse proportionality of E-cadherin and activated AKT 
expression would be expected to be observed in the MAH7 tumors. To further 
verify that the observed small MAH6 tumor size is specifically a result of the 
repression of E-cadherin expression and is not due to unrelated effects of 
activated AKT signaling, these in vivo assays will also be repeated using MAH6 
cells in which the expression of E-cadherin has been re-introduced. If the 
observed results are specific to the repression of E-cadherin then this re-
introduction of E-cadherin expression should rescue the mutant tumor phenotype 
and would be expected to result in tumor sizes that are comparable to those of 
parental DU145 cell line.      
 The multiple outputs of the PI3K/AKT signaling pathway may contribute to 
the progression of prostate cancer on various levels. The finding that the 
permanent loss of E-cadherin expression may be disadvantageous to the 
progression of prostate cancer, in addition to the observed sensitivity of E-
cadherin expression to the level of activated AKT expression may therefore 
represent a means of regulating the inhibition of E-cadherin expression by the 
PI3K/AKT signaling pathway such that a certain threshold of PI3K/AKT signaling 
may be required for the repression of E-cadherin. This hypothesis that certain 
cellular outputs are dependent upon achieving a particular AKT signaling 
threshold is supported by the findings of Segrelles et al., who examined the 
ectodermal development of myrAkt transgenic mice displaying different levels of 




level of Akt kinase activity had defects in ectodermally derived organs including 
hair, teeth, nails, and epidermal glands. However, these defects were not found 
in animals that expressed either wild-type Akt or a low level of myr-Akt — 
indicative of a low level of Akt kinase activity — suggesting that a certain 
threshold of Akt signaling is required in order to result in the observed 
developmental defects. Additionally, the concept of an Akt activity threshold is 
further supported in the study by the finding that the nuclear localization and 
overall expression of Foxo3a was dramatically reduced in the keratinocytes of 
animals expressing a high level of myr-Akt, but not in those expressing a low 
level of myr-Akt.  
 In the course of conducting the analysis described in this chapter, a study 
was published by Gan et al. in which EGFR-mediated induction of the Akt 
signaling pathway was examined in the DU145 cell line (Gan et al., 2010). Gan et 
al., demonstrated that treatment of DU145 cells with EGF resulted in EGFR 
activation as well as downstream pAKT expression, and the observation of 
mesenchymal morphological features suggestive of an EMT. Conversely, 
treatment of DU145 cells with EGF in the presence of a PI3K inhibitor resulted in 
diminished EMT characteristics, suggesting that the observed EMT was 
specifically a result of activated PI3K/AKT signaling. Further, cell border 
expression of E-cadherin was reduced in DU145 cells treated with EGF, but 
unaffected in cells treated with EGF in the presence of the PI3K inhibitor. 
Additionally, Western blot analysis showed that DU145 cells treated with EGF 




GSK3β, as well as an increase in Snail expression. This pattern of expression 
was not observed in DU145 cells treated with EGF in the presence of the PI3K 
inhibitor. siRNA knockdown of endogenous Snail expression in DU145 cells was 
shown to prevent the loss of E-cadherin expression in the presence of EGF 
treatment. Taken together these results suggest that the activation of PI3K/AKT 
signaling in DU145 cells results in a loss of E-cadherin expression in the 
presence of increased Snail expression. These results are consistent with the 
analysis presented in this chapter, thereby lending further support to the 
hypothesis that PI3K/AKT signaling may lead to the EMT-like transcriptional 
repression of E-cadherin via Snail in prostate cancer.  
 Interestingly, the results presented in this chapter suggest that PI3K/AKT 
signaling affects E-cadherin based adherens junctions at the level of E-cadherin 
expression, but does not affect DSG2 based desmosomes at the level of DSG2 
expression. The in vitro analyses in chapters IV.2 and IV.3 show that the 
expression of DSG2 was relatively unaffected by the homogenously high level of 
AKT expression and the nuclear accumulation of Snail. Further, the high level of 
DSG2 protein expression detected in MAH6 cells suggests that activated AKT 
expression similarly does not affect overall DSG2 protein expression. However, 
the reduced cell border localization of DSG2 in MAH6 cells suggests that 
activated AKT expression may impair desmosome formation. Taken together 
these results suggest that PI3K/AKT signaling may disrupt desmosome 
formation, though this disruption does not occur as a result of the loss of DSG2 




desmosomal proteins in the MAH6 cell line to determine if the disruption of 
desmosome formation occurs as a result of the loss of expression of these 
proteins.  
 The results of the in vivo analyses described in chapter IV.4 show that the 
cell border expression of DGS2 was observed in MAH6 tumors, and while this 
expression was most robust in areas with low or no activated AKT expression, a 
low level of DSG2 cell border expression could often be detected in areas of high 
activated AKT expression. The results presented in this chapter further suggest 
that PI3K/AKT signaling may affect desmosome formation, as DSG2 could not 
consistently be detected at the cell border of all activated AKT expressing cells, 
but taken together with the results of chapters IV.2 it is likely that this affect is not 
due to the loss of DSG2 expression. Taken together these results suggest that 
separate pathways may be involved in the regulation of E-cadherin and DSG2 





Materials and Methods 
 
Mice 
 Both the in vivo tumorigenesis and in vivo extravasation and metastatic 
tumor colony formation assays were performed on 5-6 week old male 
NOD.CB17-PrkdcScid mice purchased from Jackson Laboratories (The Jackson 




guidelines established by the Columbia University, Institutional Animal Care and 
Use Committee.  
 
Antibodies 
 The anti-E-cadherin mouse monoclonal antibody was purchased from 
Invitrogen (Carlsbad, CA, USA) and used at a dilution of 1:400 for 
immunofluorescence analysis of fresh fixed cells and OCT-embedded frozen 
tissue sections; a dilution of 1:1000 was used for Western Blot analysis. The anti-
DSG2 (DG3.10) mouse monoclonal antibody was purchased from Fitzgerald 
(Acton, MA, USA) and used at a dilution of 1:50 for immunofluorescence analysis 
of fresh fixed cells and OCT-embedded frozen tissue sections; a dilution of 1:500 
was used for Western blot analysis. The β-actin rabbit monoclonal antibody was 
purchased from Sigma-Aldrich (St. Louis, MI, USA) and used at a dilution of 
1:2000 for Western blot analysis. The HA-tag (C29F4) rabbit monoclonal 
antibody was purchased from Cell Signaling (Danvers, MA, USA) and used at a 
dilution of 1:400 on fresh fixed cells and OCT-embedded frozen tissue sections; 
a dilution of 1:400 was also used for Western blot analysis. The Snail rabbit 
polyclonal antibody was purchased from Abcam (Cambridge, MA, USA) and 
used at a dilution of 1:1000 on fresh fixed cells and OCT-embedded frozen tissue 
sections; a dilution of 1:1000 was also used for Western blot analysis. The Slug 
rabbit polyclonal antibody was purchased from Abcam (Cambridge, MA, USA) 
and used at a dilution of 1:500 on fresh-fixed cells. The Twist polyclonal rabbit 




dilution of 1:1000 on fresh fixed cells. The pAKT(Ser473) (clone 736E11) rabbit 
antibody was purchased from Cell Signaling (Danvers, MA, USA) and was used 
at a concentration of 1:50 on OCT-embedded frozen tissue sections.      
 
Generation of Stable Myristoylated AKT HA-tagged (MAH) Cell Lines 
 A pLNCX retroviral construct containing myristoylated HA-tagged AKT1 
was purchased from Addgene (Cambridge, MA, USA).  One day prior to 
transfection, Phoenix2™-Ampho cells (Allele Biotechnology, San Diego, CA, 
USA) were plated in 10cm plates at a density of  1 X 106 in MEM media 
containing 10% FBS. On the day of transfection, 6µg of plasmid DNA and 
FuGENE 6® transfection reagent (Roche Applied Sciences, Indianapolis, IN, 
USA) were added to cells in serum-free culture medium according to the 
manufacturer’s protocol. Two days after transfection, media from the target 
DU145 cell line was aspirated and the cells were infected once via a direct 
transfer of filtered media containing 10µg/mL Polybrene (Millipore, Billircia, MA, 
USA) from the transfected Phoenix2™-Ampho cells. This infection procedure 
was repeated twice the following day. The day after the final infection, cells were 
collected via trypsinization and split into 96-well plates. The culture media (MEM 
with 10% FBS) was changed two days after plating, and fresh media containing 
600 µg/mL Geneticin (Invitrogen, Carlsbad, CA, USA) was added for selection. 
Surviving cell lines were maintained under selective conditions and used for 






RNA and Protein Isolation 
 RNA isolation was conducted as described in chapter II.5. Protein was 
isolated as described in chapter III.6  
 
qRT-PCR 
 qRT-PCR was conducted as described in chapter II.5. Primers used for 
qRT-PCR analysis are shown in Table 1. 
 
Table 1: RT-PCR Primers and qRT-PCR Primers 
qRT-PCR Primers 
Transcript Forward Primer Reverse Primer 
E-cadherin* 5-’CAGCACGTACACAGCCCTAA-3’ 5’-ACCTGAGGCTTTGGATTCCT-3’ 
DSG2 5’-ATCAATGCAACAGATGCAGATGA-3’ 5’-TGTCAAAGTGTAGCTGCTGTGT-3’ 
Snail* 5’- CTTCCAGCAGCCCTACGAC-3’ 5’-CGGTGGGGTTGAGGATCT-3’ 
β-actin  5’-AAACTGGAACGGTGAAGGTG-3’ 5’-GTGGCTTTTAGGATGGCAAG-3’ 
*E-cadherin and Snail primers designed as reported by Chen et al., 2010.  
 
Immunofluorescence Analysis 
 Immunofluorescence analysis was conducted as described in chapter II.5.  
 
Western Blot Analysis 






In vivo Tumorigenesis Assay 
 In vivo tumorigenesis assays were conducted as described in chapter III.6.  
 
In vivo Extravasation and Metastatic Tumor Colony Formation  
 In vivo extravasation and metastatic tumor colony formation assays were 
conducted as described in chapter III.6.  
 
Statistical analysis 
 Experimental data is expressed as mean ± standard deviation; statistical 
analysis was performed using a Student’s t-test. Fisher’s exact test was used for 
the analysis of categorical data. Values were considered statistically significant at 


















































 As described in chapter I.8 the challenge of prostate cancer diagnosis and 
treatment lies in predicting the potential of a given cancer to be an aggressive 
cancer. To date, there are no established prognostic factors for prostate cancer 
beyond serum PSA determination. Therefore, there is a great need for prognostic 
biomarkers that can assist in estimating the likelihood of prostate cancer 
aggressiveness.  
 The overexpression of AKT and pAKT in prostate cancer has been 
described, and AKT/pAKT expression has been associated with biochemical 
recurrence in prostate cancer (Malik et al., 2002; Liao et al., 2003; Sun et al., 
2001; Kreisberg et al., 2004; Li et al., 2009; Bedolla et al., 2007; Ayala et al., 
2004). However, while the loss of E-cadherin expression has been described in 
prostate cancer, no large scale study has yet examined the association of E-
cadherin expression and biochemical recurrence in prostate cancer (Rubin et al., 
2001; Umbas et al., 1992). Additionally, the expression of DSG2 in prostate 
cancer has not been examined, to date. 
 The in vitro functional analysis performed in chapters IV.2 and IV.3 of this 
study demonstrated that activation of the PI3K/AKT signaling pathway can lead 
to the transcriptional repression of E-cadherin in prostate cancer, and suggested 




transcription factor Snail. Additionally, the in vivo analysis performed in chapter 
IV.4 of this study demonstrated that the expression of E-cadherin is inversely 
proportional to that of both myristoylated-AKT and Snail, further supporting the 
hypothesis that PI3K/AKT and Snail are repressors of E-cadherin expression. 
Interestingly, while this pattern of expression could be observed for DSG2, it was 
observed to a lesser degree. Taken together with the in vitro analyses performed 
in chapters IV.2 and IV.3, these results suggest that the regulation of DSG2 
expression may be separate from that of E-cadherin expression in the 
progression of prostate cancer.  
 Having performed these functional analyses I next sought to further 
examine the hypothesis that PI3K/AKT signaling may lead to the EMT-like 
transcriptional repression of E-cadherin via Snail in prostate cancer. I also 
wanted to examine the expression of DSG2 in human prostate cancer tissue 
samples to determine whether a loss of DSG2 expression similar to that 
described for E-cadherin could be observed. Additionally I wanted to determine 
whether the relationship between DSG2, activated AKT and Snail expression 
observed in chapter IV could also be observed in human prostate cancer tissue 
samples. Finally, I wanted to examine whether E-cadherin and DSG2 could serve 
as useful predictors of prostate cancer aggressiveness by determining whether 
their expression was associated with biochemical recurrence.  
 To accomplish these goals I examined the expression of E-cadherin, 
DSG2, pAKT, and Snail in a large cohort of patients with prostate cancer who 




the expression of these proteins of interest were analyzed are described in 
chapter V.2. In chapter V.3 I describe the statistical analysis performed to 
determine the expression profiles of the individual proteins of interest in primary 
prostate cancer, the correlation between the expression of the proteins of interest 
themselves, the correlation between the expression of the proteins of interest 
and clinicopathological characteristics of prostate cancer, and the association of 
the proteins of interest with biochemical recurrence. I found that, similar to E-
cadherin, there is a reduced expression of DSG2 in prostate cancer. Further 
there is a strong and statistically significant positive correlation between the 
expression of DSG2 and E-cadherin in prostate cancer, and the expression of 
these cadherins is negatively correlated with the clinicopathological features of 
prostate cancer examined. A weak correlation between the expression of E-
cadherin, pAKT, and Snail as well as DSG2, pAKT, and Snail was also observed. 
Finally, the reduced expression of both E-cadherin and DSG2 were significantly 
associated with biochemical recurrence in prostate cancer. In chapter V.4 I 
discuss the results observed for the expression of these markers and the 
potential use of both E-cadherin and DSG2 as markers of aggressive prostate 
cancer. The materials utilized for this portion of the study are further described in 











Immunofluorescence analysis of E-cadherin, DSG2, pAKT, and Snail on 
Primary Prostate Cancer Tissue Microarrays and Descriptive Statistics of 
the Cohort 
 To examine the expression of E-cadherin, DSG2, pAKT, and Snail in 
primary prostate cancer I performed immunofluorescence analysis for these 
proteins of interest on tissue microarrays (TMAs). TMAs are built using tissue 
cores, small cylinders of tissue 0.6 µm in diameter extracted from formalin-fixed 
paraffin-embedded (FFPE) tissue blocks of patient samples. As many as 250 
tissue cores embedded together in paraffin may be used to build a given TMA, 
thereby allowing for the analysis of a given protein of interest in many patient 
samples, simultaneously, in a single experiment.  
 The TMAs utilized in this study were built in the Cordon-Cardo laboratory, 
and were generated from 414 radical prostatectomy cases which were originally 
collected between September, 2000 to January, 2005  at the Henry Ford Health 
System in Detroit as part of the Gene-Environment Interaction Prostate Cancer 
Study (GECAP: NIH/NIES R01 ES11126-03). Follow-up data for these cases 
regarding evidence of biological recurrence was available for our study. To build 
the TMAs, tissue samples for each case were first reviewed by two pathologists 
in the lab to identify the areas of the sample that contained the highest density of 




tissue blocks for each patient sample. In this way, the representative cores for 
each patient sample were enriched for tumor cells. A minimum of three cores 
taken from the tumor rich regions of each patient sample were used to build the 
TMAs; therefore, each patient sample was represented in triplicate, at minimum, 
on the TMAs. TMAs including adjacent normal tissue for each patient were also 
built in the manner described. Once built, 5µm sections were cut from the TMA 
paraffin blocks and immunofluorescence analysis was performed for each protein 
of interest. The TMAs were then scored with Dr. Mireia Castillo-Martin, a 
pathologist in the Cordon-Cardo laboratory. The expression of the proteins of 
interest was scored by estimating the percentage of tumor cells with 
immunoreactivity per tissue core (Figure 1). The average values of the 
representative cores from each patient sample were then used for the statistical 
analyses described in chapter V.3. The clinical characteristics of the patients 





Figure 1: Schematic depiction of a TMA and TMA scoring. Up to 250 tissue cores may 
be used to build a TMA (A). Each patient case is represented by a minimum of three 
tissue cores (B). Immunofluorescence analysis (depicted here in red) is used to 
examine the expression of each protein of interest. Each tissue core is scored by 
estimating the percentage of tumor cells with immunoreactivity per tissue core. The 
final score for the marker of interest in a given patient sample is the average value of 











Descriptive Statistics and Expression of E-cadherin, DSG2, pAKT, and 
Snail in Primary Prostate Cancer 
 To assess the expression of the proteins of interest in prostate cancer as 
compared to normal prostate tissue, I performed immunofluorescence analysis 
for each protein of interest on prostate cancer TMAs for the entire cohort (n = 
414) as well as normal prostate TMAs for a subset of the cohort (n = 50, E-
cadherin and DSG2; n = 91, pAKT and Snail) (Table 2; Figure 2). In addition to 
an antibody for the protein of interest, an antibody for CK8/18 — keratins found in 
both normal prostate luminal epithelial cells and adenocarcinoma cells — was 
also included on each TMA as a means of identifying the epithelial cells in each 
sample.  
 A significant decrease in the expression of E-cadherin was found in 
prostate cancer as compared to normal prostate, consistent with the reported 
reduced expression of E-cadherin in prostate cancer (Rubin et al., 2001; Umbas 
et al., 1992). While the cell border expression of E-cadherin was generally high in 
well differentiated areas of the tumor, this expression was often much lower in 
poorly differentiated areas of the tumor (Figure 3). Interestingly, there is also a 
significant decrease in the expression of DSG2 in prostate cancer as compared 
to normal prostate. Similar to the pattern of E-cadherin expression, the cell 
border expression of DSG2 was generally high in areas of the tumor that were 




differentiated (Figure 4). Conversely, a significant increase in pAKT expression 
was detected in prostate cancer as compared to normal prostate, a result that is 
consistent with the reported increase of pAKT expression in prostate cancer 
(Malik et al., 2002; Liao et al., 2003; Sun et al., 2001). This pAKT expression was 
detected in both the cytoplasm and the nucleus and was generally high in both 
well and poorly differentiated areas of the tumor (Figure 5). Additionally, there 
was a slight but significant increase in the nuclear expression of Snail in prostate 
cancer as opposed to normal prostate consistent with the reported increase of 















Figure 2: Histogram depicting the number of cases within the cohort (y-axis) with positive 





Figure 3: Immunofluorescence analysis of E-cadherin and CK8/18 in prostate cancer TMAs. The 
cell border expression of E-cadherin is high in well differentiated areas of the tumor and low in 
poorly differentiated areas of the tumor. E-cadherin is shown in red, CK8/18 is shown in green, 






Figure 4: Immunofluorescence analysis of DSG2 and CK8/18 in prostate cancer TMAs. The cell 
border expression of DSG2 is high in well differentiated areas of the tumor and low in poorly 
differentiated areas of the tumor. DSG2 is shown in red, CK8/18 is shown in green, and DAPI is 







Figure 5: Immunofluorescence analysis of pAKT and CK8/18 in prostate cancer TMAs. The 
expression of pAKT can be detected in the nucleus and cytoplasm and is high in both well 
differentiated and poorly differentiated areas of the tumor. pAKT is shown in red, CK8/18 is 

























Figure 6: Immunofluorescence analysis of Snail and CK8/18 in prostate cancer TMAs. Here the 
nuclear expression of Snail is more often detected in cancer cells than in normal prostate 
epithelium (as indicated by the letter N). Snail is shown in red, CK8/18 is shown in green, and 















Correlation for the Expression of Proteins of Interest and 
Clinicopathological Characteristics of Prostate Cancer Patients 
 Having examined the expression of E-cadherin, DSG2, pAKT, and Snail in 
the cohort, I next wanted to determine whether there was a correlation between 
the expression of the proteins of interest themselves, as well as whether there 
was a correlation between the expression of the proteins of interest and 
clinicopathological characteristics most commonly associated with aggressive 
prostate cancer including serum PSA concentration, Gleason score, and 
pathological stage (Quinn et al., 2001) (Table 3). This analysis was performed 
using Spearman’s rank correlation. Interestingly, there was a strong and 
significant positive correlation between the expression of E-cadherin and DSG2, 
therefore suggesting that as the expression of E-cadherin decreases in prostate 
cancer so too does the expression of DSG2.  
 A weak but significant positive correlation between the expression of 
pAKT and the expression of Snail was detected, suggesting that as the 
expression of pAKT increases so too does the nuclear expression of Snail. 
Contrary to the results of the in vitro and in vivo functional analysis performed in 
chapter IV, there was a weak but significant positive correlation between the 
expression of pAKT and the expression of E-cadherin. There was also very weak 
positive correlation between the expression of pAKT and DSG2, weaker than that 
of pAKT and E-cadherin; however, this correlation was not significant. These 
results suggest that the expression of E-cadherin and DSG2 increase as pAKT 




performed in chapter IV, which suggest the opposite relationship. There was also 
a very weak negative correlation between E-cadherin and Snail. Though this 
correlation was not significant, it was consistent with the reduced expression of 
E-cadherin detected in cells with high nuclear Snail expression observed in 
chapter IV.2, as well as the inverse expression pattern of E-cadherin and Snail 
observed in chapter IV.4. Additionally, there is a very weak positive correlation 
between DSG2 and Snail; though this correlation is not significant, it is consistent 
with observation in chapter IV.2 that there is no reduction in level of DSG2 
expression in cells with high nuclear Snail expression, further suggesting that the 
expression of Snail does not affect the expression of DSG2 in prostate cancer.   
 Interestingly, though not significant, there was a negative correlation 
between E-cadherin expression and all the clinicopathological features 
examined. A negative correlation was also observed for DSG2 expression and all 
the clinicopathological features examined. This correlation was significant for 
both serum PSA concentration and Gleason score, and slightly stronger that the 
correlation observed between E-cadherin and these same features. Taken 
together, these results suggest that the expression of both E-cadherin and DSG2 
decrease as the level of serum PSA concentration increases, as well as in cases 







Table 3: Examining the correlation between the proteins of interest and clinicopathological 
characteristics using Spearman’s rank correlation. There is a strong and significant positive 
correlation between the expression of E-cadherin and DSG2 (ρ = 0.498**). There is a weak but 
significant positive correlation between the expression of pAKT and Snail (ρ = 0.129*). There is a 
weak but significant positive correlation between pAKT and E-cadherin (ρ = 0.134*), and a very 
weak positive correlation between pAKT and DSG2 which is not significant (ρ = 0.053). There is a 
very weak negative correlation between E-cadherin and Snail (ρ = -0.025) and a very weak 
positive correlation between DSG2 and Snail (ρ = 0.033), neither of which are significant. 
Interestingly there is a negative correlation between both DGS2 and E-cadherin and all 
clinicopathological features examined.  
 
 
Clinical Implications of the Expression of Proteins of Interest 
 Having examined the correlation between the proteins of interest and 
clinicopathological features of prostate cancer, I next wished to determine 
whether these proteins of interest are associated with biochemical recurrence. 
This analysis was performed using the log-rank test, and Kaplan-Meier survival 
curves were plotted. To examine E-cadherin, I compared cases with high E-
cadherin expression (≥ 70%) to those with low E-cadherin expression (<70%).  A 




approximate mean expression value observed for E-cadherin in this prostate 
cancer cohort (Table 2). Importantly, <70% E-cadherin expression was not 
observed in the normal prostate cases examined thereby emphasizing the utility 
of this cut-off value (Table 3). Interestingly, patients expressing ≥70% E-cadherin 
had a higher rate of recurrence free survival than those expressing <70% E-
cadherin and the difference between these two groups was statistically significant 
(Figure 7, P = 0.043). Patients with <70% E-cadherin expression had a median 
time to biochemical recurrence of 104 months, while those with ≥70% E-cadherin 
expression did not reach the median time to biochemical recurrence after a 
follow-up time of 120 months. To examine DSG2, I compared cases with high 
DSG2 expression (≥ 60%) to those with low DSG2 expression (<60%). A cut-off 
value of 60% was utilized as this was the approximate mean expression value 
observed for DSG2 in this prostate cancer cohort (Table 2). Importantly, <60% 
DSG2 expression was only observed in 2% of the normal prostate cases 
examined, thereby emphasizing the utility of this cut-off value (Table 3). Much 
like E-cadherin, patients expressing ≥ 60% DSG2 had a higher rate of recurrence 
free survival than those expressing < 60%, and the difference between these two 
groups was statistically significant (Figure 8, P = 0.01). Patients with <60% DSG2 
expression had a median time to biochemical recurrence of 104 months, while 
those with ≥60% DSG2 expression did not reach the median time to biochemical 
recurrence after a follow-up time of 120 months. Taken together, these results 




recurrence in prostate cancer, therefore suggesting that E-cadherin and DSG2 
may be useful prognostic markers of aggressiveness for prostate cancer.  
 To examine pAKT, I compared cases that did not express pAKT (and were 
therefore considered negative for pAKT expression) to those that did express 
pAKT (and were therefore considered positive for pAKT expression). Importantly, 
pAKT expression was observed in significantly fewer normal prostate cases 
(38%) as compared to prostate cancer cases (67%), thereby emphasizing the 
utility of this cut-off value (Table 3). Patients who were negative for pAKT 
expression had a higher rate of recurrence-free survival than those who were 
positive for pAKT expression, and the difference between these two groups was 
nearly statistically significant (Figure 9, P = 0.078). Patients who were positive for 
pAKT expression had a median time to biochemical recurrence of 106 months, 
while those who were negative for pAKT expression did not reach the median 
time to biochemical recurrence after a follow-up time of 120 months. To examine 
Snail, I compared cases that did not express Snail (and were therefore 
considered negative for Snail expression) to those that did express Snail (and 
were therefore considered positive for Snail expression). Though there was a 
slight but significant increase in the mean expression value for Snail in prostate 
cancer as compared to normal prostate, as shown in Table 2, a significant 
difference in positive Snail expression in normal prostate cases (40%) as 
compared to prostate cancer cases (36%) was not detected (Table3). 
Accordingly, while patients who were negative for Snail expression had a higher 




expression, there was not a significant difference between these two groups 
(Figure 10, P = 0.263). Patients who were positive for Snail expression had a 
median time to recurrence of 106 months, while those who were negative for 
Snail expression did not reach the median time to biochemical recurrence after a 
follow-up time of 120 months. Taken together these results suggest that pAKT 
expression is associated with biochemical recurrence in prostate cancer and that 
this association is very nearly statistically significant, indicating that pAKT may 
serve as a useful prognostic marker of aggressiveness in prostate cancer. 
Though taken as a whole, these results indicate that E-cadherin and DSG2 are 
the most useful markers of prostate cancer aggressiveness examined in this 









Figure 7: Kaplan-Meier survival curve for E-cadherin. Patients expressing ≥70%                     
E-cadherin had a higher rate of recurrence free survival than those expressing <70%              
E-cadherin and the difference between these two groups is statistically significant.   
 
 
Figure 8: Kaplan-Meier survival curve for DSG2. Patients expressing ≥60% DSG2 
had a higher rate of recurrence free survival than those expressing <60% DSG2 and 







Figure 9: Kaplan-Meier survival curve for pAKT. Patients negative for pAKT 
expression had a higher rate of recurrence free survival than those with positive 




Figure 10: Kaplan-Meier survival curve for Snail. Patients negative for Snail 
expression had a higher rate of recurrence free survival than those with positive Snail 









 The results of the analyses performed in chapter IV suggest that 
PI3K/AKT signaling may mediate the transcriptional repression of E-cadherin in 
prostate cancer via Snail. These results also suggest that the regulation of E-
cadherin expression may be separate from that of DSG2 expression, as 
PI3K/AKT signaling does not appear to negatively affect the level of DSG2 
expression. In chapter V.3, using Spearman’s rank correlation a very weak 
negative correlation was observed for the expression of E-cadherin and Snail, 
while a weak positive correlation was observed for DSG2 and Snail. These 
results support the hypothesis that Snail may act as a transcriptional repressor of 
E-cadherin expression in prostate cancer, and that Snail is not involved in the 
repression of DSG2 expression in prostate cancer. Though a weak but significant 
positive correlation was observed for the expression of pAKT and E-cadherin, 
contrary to what was predicted by my hypothesis, given the many potential roles 
of PI3K/AKT signaling in prostate cancer progression coupled with the various 
means by which the expression of E-cadherin may be inhibited, these results 
may imply that PI3K/AKT signaling is but one of a variety of mechanisms by 
which E-cadherin expression is inhibited in prostate cancer.   
 While the loss of E-cadherin expression has been previously reported in 
prostate cancer, a large scale analysis of the utility of this cadherin in predicting 




this study, the expression of desmosomal cadherins in prostate cancer had not 
been examined. Given that both adherens junctions and desmosomes are 
involved in cell-cell adhesion in prostatic epithelium, an understanding of the 
expression of both classical cadherins and desmosomal cadherins would provide 
a deeper insight into the role of anchoring junctions in prostate cancer 
progression. Interestingly, DSG2 expression was significantly reduced in prostate 
cancer as opposed to normal prostate. Much like E-cadherin, the expression of 
DSG2 was generally high in well differentiated areas of the tumor and low in 
poorly differentiated areas of the tumor. Consistent with this observation, the 
results of the Spearman’s rank correlation show that there is a strong positive 
correlation between the expression of E-cadherin and DSG2. Further, there is a 
negative correlation between the expression of these cadherins and serum PSA 
concentration, Gleason score, and pathological stage. Taken together these 
results suggest that cadherin expression is reduced in the poorly differentiated 
cells of primary prostate tumors. Taken together with the results of the Kaplan-
Meier survival curves, these results further suggest that tumor cells with reduced 
cadherin expression are more likely to be aggressive and would therefore 
possess a greater potential for metastatic behavior than those cells with a high 
level of cadherin expression. These results highlight a potentially critical role for 
cadherin based cell-cell adhesion in the progression of prostate cancer, and 
demonstrate that both E-cadherin and DSG2 may be useful prognostic markers 







Materials and Methods 
Antibodies 
 The anti-E-cadherin mouse monoclonal antibody was purchased from 
Invitrogen (Carlsbad, CA, USA) and used at a dilution of 1:400 for 
immunofluorescence analysis of FFPE TMA sections. The anti-DSG2 (DG3.10) 
mouse monoclonal antibody was purchased from Fitzgerald (Acton, MA, USA) 
and used at a dilution of 1:20 for immunofluorescence analysis of FFPE TMA 
sections. The pAKT(Ser473) (clone 736E11) rabbit antibody was purchased from 
Cell Signaling (Danvers, MA, USA) and was used at a concentration of 1:50 for 
immunofluorescence analysis of FFPE TMA sections. The Snail rabbit polyclonal 
antibody was purchased from Abcam (Cambridge, MA, USA) and used at a 
dilution of 1:800 for immunofluorescence analysis of FFPE TMA sections. The 
CK8/18 guinea pig polyclonal antibody was purchased from Progen (Heidelberg, 
Germany) and used at a concentration of 1:100 for immunofluorescence analysis 
of FFPE TMA sections.  
 
Immunofluorescence Analysis of FFPE TMA sections 
 TMAs were built as described in chapter V.2, and 5µm sections were cut 
from each TMA FFPE block for analysis. The slides were deparaffinized and 
rehydrated, and antigen retrieval was performed by heating slides in a steamer in 




temperature, washed under running tap water for 1 minute, and then washed 
once in 1X PBS. Slides were incubated in 0.1% Triton X-100/ 1% BSA/ 1X PBS 
block at room temperature for 1 hour. Block was then aspirated, primary antibody 
was added, and slides were incubated overnight at 4ºC. The following day, slides 
were washed in 1XPBS with agitation, then a 1:600 dilution of secondary 
antibody, either Alexa Fluor® 594 or Alexa Fluor® 488 (Invitrogen, Carlsbad, CA, 
USA), was added and slides were incubated at room temperature for 45 min. 
Slides were then washed three times in 1X PBS + 0.1% Triton with agitation, 
washed three times in 1X PBS to remove detergent, immersed briefly in water 
and mounted using VECTASHIELD® mounting medium with DAPI (Vector 
Laboratories, Burlingame, CA, USA). TMAs were then scored in the manner 
described in chapter V.2.   
 
Statistical Analysis 
 Statistical analysis was conducted using SPSS v18.0 (SPSS Inc., 
Chicago, IL, USA). The Student’s t-test was used to compare the expression of 
the proteins of interest in primary prostate cancer and normal prostate tissue. 
Spearman’s rank correlation was used to analyze the correlations between 
proteins of interest and clinicopathological features. Biochemical recurrence was 
analyzed using Kaplan-Meier survival curves, and curves were compared using 


































The Role of Cell-Cell Adhesion in Aggressive Prostate Cancer 
 Adherens junctions and desmosomes play a crucial role in the 
development and maintenance of normal tissues, and the importance of these 
cell-cell junctions is underscored by the developmental aberrations and human 
diseases resulting from their disregulation. Desmosomes and desmosomal 
cadherins have been extensively examined in the epidermis and epidermal 
appendages, and aberrations of desmosomal cadherins are known to be 
associated with diseases of the skin, hair, and heart. However, little is known 
regarding the expression of desmosomal cadherins in other epithelial tissues. In 
the prostate, the presence of desmosomes has been described, though the 
expression profile of desmosomal cadherins had not been characterized prior to 
this study (Fisher and Jeffrey, 1965).  
 In chapter II, I examined the expression of desmosomal cadherins in 
normal human prostate and found that, though most desmosomal cadherins are 
expressed in the prostate at the RNA level, only DSG2, DSC2, and DSG4 
expression can be detected in the prostate at the protein level. Further, the 
expression of DSG2 and DSG4 was found to be largely restricted to the luminal 
cells of the prostate. Interestingly, the expression of DSG2 was present in 
metastatic prostate cancer cell lines in vitro, while the expression of DSG4 was 




DSG2 in most cancer cell lines examined may illustrate a requirement for 
desmosomal adhesion in metastatic prostate cancer cells.    
 In cancer, the role of E-cadherin as a tumor suppressor has been well 
established. The downregulation or loss of E-cadherin expression is a common 
occurrence in many types of cancer, and the role of E-cadherin as a suppressor 
of invasive behavior has been demonstrated both in vitro and in vivo (Berx and 
van Roy, 2009; Vleminckx et al., 1991; Perl et al., 1998). Conversely, the role of 
desmosomal cadherins in cancer is less well understood; the loss of expression, 
de novo expression, and overexpression of desmosomal cadherins has been 
reported in various types of cancer (Biedermann et al., 2005; Yashiro et al., 
2006; Ramani et al., 2008; Oshiro et al., 2005; Khan et al., 2006; Kurzen et al., 
2003; Chen et al., 2007). In prostate cancer, the reduced expression of E-
cadherin has been reported, though the association of E-cadherin expression 
and biochemical recurrence had not been examined prior to this study (Rubin et 
al., 2001; Umbas et al., 1992). Additionally, the expression of desmosomal 
cadherins in prostate cancer had not been examined prior to this study. 
 In chapter V, I examined the expression of E-cadherin and DSG2 in 
primary tumors from a large cohort of patients with prostate cancer who 
underwent radical prostatectomy. Interestingly, much like the expression of E-
cadherin, the expression of DSG2 was found to be significantly reduced in 
primary prostate cancer as compared to normal prostate tissue. Additionally, 
there was a strong and significant positive correlation between the expression of 




cadherin decreases in primary prostate cancer, so too does the expression of 
DSG2. The expression of both cadherins was generally detected in well 
differentiated areas of the tumors, but was often reduced or lost in poorly 
differentiated areas of the tumors. Further, a negative correlation was found 
between the expression of E-cadherin and DSG2 and clinicopathological features 
of prostate cancer. These results suggest that cadherin expression is reduced in 
the poorly differentiated cells of primary prostate tumors.  
  Importantly, the reduced expression of both E-cadherin and DSG2 was 
found to be significantly associated with biochemical recurrence in prostate 
cancer. These results support the pre-established role of E-cadherin as a tumor 
suppressor in prostate cancer and also demonstrate for the first time a role for 
DSG2 as a tumor suppressor in prostate cancer. The significant association of 
reduced E-cadherin and DSG2 expression with biochemical recurrence suggests 
that these cadherins may serve as useful markers of aggressive prostate cancer. 
Taken together with the pattern of cadherin expression in prostate tumors, as 
well as the negative correlation of cadherin expression and clinicopathological 
features of prostate cancer, these results further suggest that tumor cells with 
reduced cadherin expression are more likely to be aggressive and would 
therefore possess a greater potential for metastatic behavior than tumor cells that 
have retained a high level of cadherin expression. These results highlight a 
potentially critical role for cadherin based cell-cell adhesion in the progression of 




    While the assembly of adherens junctions has been extensively studied, 
less is known regarding the assembly of desmosomes. Previous studies have 
demonstrated that the formation of adherens junctions precedes that of 
desmosomes both in early development as well as in the de novo assembly of 
cell-cell anchoring junctions; additionally, the formation of desmosomes is 
commonly believed to be dependent upon the prior formation of adherens 
junctions (Ohsugi et al., 1996; Jackson et al., 1980; Fleming et al., 1991; 
Vasioukhin et al., 2000). The strong and significant correlation between the 
reduced expression of E-cadherin and DSG2 in primary prostate cancer 
observed in this study coupled with the findings of previous studies examining 
adherens junction and desmosome assembly in development and de novo cell-
cell anchoring junction formation, suggests that the reduced expression of DSG2 
observed in primary prostate cancer may result from the prior loss of E-cadherin 
expression and therefore the loss of E-cadherin based adherens junctions.  
 In chapter III, I examined the hypothesis that the loss of E-cadherin based 
adherens junctions in prostate cancer results in the loss of desmosomal 
adhesion. Surprisingly, the loss of E-cadherin expression in prostate cancer cells 
in vitro did not alter the expression of DSG2, therefore suggesting that the loss of 
E-cadherin based adherens junctions in prostate cancer does not result in the 
reciprocal loss of desmosomes. This result also suggests that, while adherens 
junction assembly precedes that of desmosomes in early development as well as 
de novo anchoring junction formation, the formation of desmosomes does not 




 Further, in vivo analysis of prostate tumor xenografts lacking the 
expression of E-cadherin revealed that the loss of E-cadherin based adherens 
junctions results in a dramatic reduction in the size of tumors formed, despite the 
retention of desmosomal adhesion. In vivo analysis of extravasation and 
metastatic tumor colony formation revealed that prostate cancer cells lacking the 
capacity to form E-cadherin based adherens junctions are able to form metastatic 
tumor colonies, therefore suggesting that extravasation is not impaired by the 
loss of E-cadherin. However, this analysis further showed that significantly fewer 
animals injected with cells lacking E-cadherin expression are able to form 
metastatic tumor colonies, and that the size of the metastatic tumor colonies that 
were able to form was significantly smaller than those formed by cells which 
retained E-cadherin expression. These results suggest that the loss of E-
cadherin inhibits metastasis at the level of metastatic tumor colony formation.    
 While the results of the functional analyses performed in chapter III 
suggest that the formation of desmosomes is not dependent upon prior formation 
of adherens junctions, the positive correlation between the expression of E-
cadherin and DSG2 discovered in chapter V raises the question: are adherens 
junctions affected by the loss of desmosomal adhesion in prostate cancer? The 
foremost future direction of this portion of the study is therefore to examine E-
cadherin based adherens junctions in a prostate cancer environment lacking 
desmosomal adhesion. To accomplish this goal I will knockdown the expression 
of DSG2 via the same approach utilized for the knockdown of E-cadherin, and 




of this study will provide insight into whether the formation of adherens junctions 
is dependent upon the formation of desmosomes in prostate cancer. These 
results will also allow for a better understanding as to whether the role of DSG2 
in prostate cancer is strictly that of a tumor suppressor, or whether DSG2 is 
associated with the same tumor promoting capabilities as E-cadherin. If 
tumorigenesis and metastatic tumor formation are unimpaired or enhanced in 
prostate cancer cells lacking DSG2 expression, these results would support the 
role of DSG2 in prostate cancer as strictly that of a tumor suppressor. If 
tumorigenesis and metastatic tumor formation are impaired in prostate cancer 
cells lacking DSG2 expression, then this would suggest that both E-cadherin and 
DSG2 have a dual role in the progression of prostate cancer in addition to their 
roles as tumor suppressors.   
 In summary, these findings shed a new light on the role of cell-cell 
anchoring junctions in prostate tumorigenesis and metastatic prostate tumor 
colony formation. The results of the analysis performed on human prostate 
cancer tissue samples in chapter V support the pre-established role of E-
cadherin as a tumor suppressor in prostate cancer and introduce for the first time 
the role of DSG2 as a tumor suppressor in prostate cancer. While the role of 
DSG2 as a tumor suppressor is further supported by the results of the functional 
analyses presented in chapter III, these results also suggest a novel role for E-
cadherin based adherens junctions in the promotion of primary and metastatic 
tumor formation. Taken together, these results show that E-cadherin and DSG2 




cadherin may in fact be required for the initial formation of primary prostate 
tumors. The expression of E-cadherin and DSG2 is then reduced in tumor cells, 
quite possibly in tumor cells with the greatest potential for metastatic behavior, 
thereby allowing for the progression from a tumor mass confined to the prostate 
capsule to a metastatic cancer. Following extravasation, the expression of E-
cadherin and DSG2 may then again increase to accommodate the formation of 



















Figure 1: A model of the expression of E-cadherin and DSG2 in the progression of prostate 
cancer. (Adapted from Shen and Abate-Shen, 2010; Thiery et al., 2002) 
 
 
The Regulation of Cell-Cell Adhesion in Aggressive Prostate Cancer 
 The dual role of E-cadherin in the suppression of invasive tumor cell 
behavior and promotion of primary and metastatic tumor formation suggests that 
the repression of E-cadherin expression in primary prostate tumors observed in 
chapter V may need to be a transient event. One such mechanism by which E-




include reversibility and the downregulation of E-cadherin. Towards this point, the 
expression of the EMT-associated transcription factor Snail has been associated 
with the downregulation of E-cadherin in breast and colorectal cancer while the 
transcriptional repression of E-cadherin via Snail has been demonstrated in a 
variety of cancer cell lines in vitro (Blanco et al., 2002; Cheng et al., 2001; Pena 
et al., 2005; Cano et al., 2000; Batlle et al., 2000). The potential requirement for 
transient repression of E-cadherin expression in the progression of prostate 
cancer coupled with the demonstrated significance of PI3K/AKT signaling in the 
progression of prostate cancer and the association of this signaling with EMT-like 
events in several other types of cancer, led me to hypothesize that PI3K/AKT 
signaling may lead to the EMT-like transcriptional repression of E-cadherin via 
Snail in prostate cancer (Di Cristofano, 1998; Di Cristofano 2001; Kim et al., 
2002; Abate-Shen et al., 2003; Majumder et al., 2003; Irie et al., 2005; Ju et al., 
2007; Grille et al., 2003; Grille et al., 2003; Zhou et al., 2004) .      
 In chapter IV the stable overexpression of activated AKT in a metastatic 
prostate cancer cell line in vitro was associated with a significant reduction in E-
cadherin expression as well as a dramatic increase in the nuclear accumulation 
of Snail, an indication of increased Snail activity. Additionally, in vivo analysis of 
prostate tumor xenografts demonstrated that tumors formed by activated AKT 
expressing cells were significantly smaller than those formed by control cells, 
though these tumors were unexpectedly positive for the expression of E-
cadherin. Further analysis revealed that there appears to be an inverse 




that areas of the tumor with high levels of AKT expression generally showed low 
or no expression of E-cadherin. This inverse correlation could also be observed 
for the expression of Snail versus the expression of E-cadherin. Finally, in vivo 
analysis of extravasation and metastatic tumor colony formation showed that 
significantly fewer animals injected with activated AKT expressing cells formed 
metastatic tumor colonies as compared to the control animals, and those animals 
that did form tumors formed significantly fewer tumors than the control animals. 
In light of the observed small size of E-cadherin positive prostate tumor 
xenografts formed by activated AKT expressing cells, this result may suggest 
that that the formation of primary and metastatic tumors by activated AKT 
expressing cells occurs via the selection and expansion of a rare, E-cadherin 
positive cell population. Taken together, the results of the in vitro analysis and 
the inverse pattern of expression observed for E-cadherin and activated AKT as 
well as E-cadherin and Snail in prostate tumor xenografts support the hypothesis 
that PI3K/AKT signaling may lead to the EMT-like transcriptional repression of E-
cadherin via Snail in prostate cancer. Additionally, the small size of both the 
prostate tumor xenografts and metastatic tumor colonies formed by activated 
AKT expressing cells further supports the concept that E-cadherin plays a 
positive role in the formation of primary and metastatic tumors.  
 In chapter V, the expression of pAKT was associated with biochemical 
recurrence in prostate cancer and this association was nearly significant. This 
result is consistent with the importance of PI3K/AKT signaling in aggressive 




2009; Bedolla et al., 2007; Ayala et al., 2004). Though a very weak negative 
correlation was found between E-cadherin and Snail expression, a weak but 
significant positive correlation was observed for the expression of pAKT and E-
cadherin. This finding is inconsistent with the hypothesis that PI3K/AKT mediated 
signaling may lead to the transcriptional repression of E-cadherin. However, 
taken together with the functional analyses performed in chapter IV, this result 
may suggest that while PI3K/AKT signaling can lead to the transcriptional 
repression of E-cadherin in prostate cancer, this repression may also be 
mediated either entirely or in part by other mechanisms.  
 Given the many potential roles of PI3K/AKT signaling in prostate cancer 
progression, coupled with the fact that the analysis of activated AKT expression 
performed in chapter IV was conducted in a prostate cancer cell line which, by its 
nature, contains many disregulated signaling pathways, it is possible that the 
observed transcriptional repression of E-cadherin by activated AKT is context-
dependent insofar as it relies upon the joint activation of other pathways not 
identified in this study. One possibility is that the transcriptional repression of E-
cadherin by activated AKT signaling in prostate cancer requires the joint 
activation of the Ras/MAPK signaling pathway. Activated RTKs can be bound by 
the SH2 domain adaptor protein GRB2, which in turn can bind to SOS. SOS acts 
as a guanine nucleotide exchange factor and therefore is an activator of Ras 
(Bar-Sagi, 1994). In this way, activated RTK signaling is coupled to the activation 
of the Ras/MAPK signaling pathway as well as the PI3K/AKT signaling pathway. 




pathway as, in addition to activating the Ras/MAPK signaling pathway, activated 
Ras can also bind to PI3K and recruit it to the membrane thereby allowing for the 
activation of PI3K/AKT signaling (Rodriguez-Viciana et al., 1994). Importantly, 
there is evidence to suggest that the joint activation of the Ras/MAPK and 
PI3K/AKT signaling pathways is involved in EMT. The EMT-like loss of adherens 
junctions and cell scattering was observed in NBT-II rat bladder carcinoma cells 
treated with HGF/SF, and this loss of adherens junctions could be blocked by 
inhibitors of PI3K or dominant negative mutants of MAPK suggesting that the 
activation of both PI3K and MAPK are required for the loss of adherens junctions 
(Potempa et al., 1998).  
 The observed weak negative correlation between the expression of E-
cadherin and Snail in primary prostate tumors could imply that EMT associated 
transcription factors other than Snail may be involved in the downregulation of E-
cadherin expression. For example, the EMT associated transcription factors Slug 
and Twist have been associated with reduced expression of E-cadherin in cancer 
and have been shown to directly inhibit the expression of E-cadherin in vitro 
(Uchikado et al., 2005; Hajra et al., 2002; Bolos et al., 2002; Yang et al., 2004). 
While PI3K/AKT signaling has been associated with the activation of Snail, Slug 
and Twist, the activation of these transcription factors by other signaling 
pathways has also been demonstrated (Saegusa et al., 2009; Vichalkovski et al., 
2010). This raises the possibility that the reduced expression of E-cadherin in 




transient inhibition of E-cadherin expression by pathways other than the 
PI3K/AKT.  
 An example of such a pathway is the TGFβ signaling pathway which has 
been well characterized as an inducer of EMT. Activation of the TGFβ pathway 
has been shown to induce the expression of Snail, Slug, and Twist via the 
SMAD-mediated expression of HMGA2 (Zavadil et al., 2005; Thuault et al., 
2006). Additionally, the Notch signaling pathway has also been implicated in the 
EMT-like repression of E-cadherin expression. In vitro analysis of the SKOV-3 
ovarian cancer cell line demonstrated that the Notch signaling pathway is able to 
induce EMT via the direct upregulation of Snail by the Notch intracellular domain 
(NICD) resulting in reduced E-cadherin expression (Sahlgren et al., 2008). 
Moreover, the Hedgehog (Hh) signaling pathway has been implicated in the 
induction of EMT as upregulation of Snail expression in the presence the Hh 
pathway effector Gli has been demonstrated in vitro (Li et al., 2006). Finally, the 
Wnt signaling pathway is known to be involved in the positive regulation of EMT-
associated transcription factors in two ways. First, β-catenin/TCF signaling leads 
to the direct upregulation of both Twist and Snail (Howe et al., 2003; Vallin et al., 
2001; Conacci-Sorrell et al., 2003). Second, like the PI3K/AKT pathway, 
activated Wnt signaling inhibits GSK3B, an inhibitor of Snail, thereby allowing for 
Snail activation (Zhou et al., 2004). Much like the PI3K/AKT and Ras/MAPK 
pathways, crosstalk between the aforementioned signaling pathways has been 
implicated in EMT in cancer. For example, crosstalk between the TGFβ signaling 




pathway, and the Wnt pathway has been observed (Bakin et al., 2000; Janda et 
al., 2002;  Zavadil et al., 2004; Eger et al., 2004). Additionally, crosstalk between 
the Notch and Hh signaling pathways has also been demonstrated (Kasper et al., 
2006). The variety of EMT-associated signaling pathways, as well as the many 
ways in which these pathways have been shown to communicate, illustrate the 
complexity of the regulation of EMT in cancer and suggest that it may be 
necessary to broaden the focus of EMT-mediated E-cadherin repression to 
include several signaling pathways and/or EMT associated transcription factors 
in addition to the PI3K/AKT signaling pathway and Snail.  
 It should also be noted that the downregulation of E-cadherin expression 
in primary prostate cancer may be due to processes unrelated to the 
transcriptional repression of E-cadherin. For example, the homeostasis of 
adherens junctions involves the recycling of E-cadherin via endocytosis which 
enables the movement of E-cadherin to new sites of cell-cell contact (Bryant and 
Stow, 2004). The activation of tyrosine kinases has been found to result in the 
phosphorylation of E-cadherin followed by the ubiquitination and degradation of 
E-cadherin mediated by the E3 ubiquitin ligase Hakai (Behrens et al., 1993; 
Fujita et al., 2002). Additionally, in vitro analysis of IGF2 signaling has been 
shown induce EMT in NBT-II cells whereby the loss of E-cadherin expression is 
due to the internalization of E-cadherin complexed with β-catenin and IGF1R 
followed by the lysosome mediated degradation of E-cadherin (Morali et al., 




due to the post-translational modification and subsequent degradation of E-
cadherin. 
 Interestingly, the in vitro analysis of DSG2 in chapter IV.2 in addition to the 
very weak and insignificant positive correlation between DSG2 and pAKT 
expression observed in chapter V suggests that the reduced expression of DSG2 
in primary prostate cancer is not associated with regulation by the PI3K/AKT 
signaling pathway. Given that the results of the analyses performed in chapter III 
demonstrate that the loss of E-cadherin based adherens junctions also has no 
effect on the expression of DSG2, these results further suggest that the reduced 
expression of E-cadherin and DSG2 observed in prostate cancer may be 
regulated separately. This then raises the question: what regulates the loss of 
DSG2 expression in prostate cancer? Given that the expression of DSG2 was 
reduced in primary prostate cancer yet found to be expressed at the cell border 
in most metastatic prostate cancer cell lines, it is likely that, much like E-
cadherin, the downregulation of DSG2 in prostate cancer may need to be a 
transient event. Though Snail was found to have no effect on the expression of 
DSG2 in this study, it is still possible that the downregulation of DSG2 is 
mediated by EMT associated transcription factors. The most obvious candidate is 
Slug, as the overexpression of Slug in NBT-II cells has been shown to result in 
the disappearance of DP and DSG2 from sites of cell-cell contact (Savagner et 
al., 1997). Future studies will therefore focus on examining the correlation 






Though both adherens junctions and desmosomes are required for the 
development and maintenance of normal tissues, and the loss of cell-cell 
adhesion is commonly observed in the progression of cancer, traditionally the 
study of cell-cell adhesion in cancer has focused solely on adherens junctions. 
This study is the first to examine the expression of desmosomal cadherins in 
both normal prostate tissue and prostate cancer. This is also the first study to 
examine the association of E-cadherin and DSG2 expression with biochemical 
recurrence in prostate cancer. Importantly, the results of this study illustrate that 
these cadherins may serve as useful markers of aggressive prostate cancer.  
Further, this study provided evidence for a new role for E-cadherin in promoting 
the formation of primary and metastatic tumors. The dual role of E-cadherin as a 
both a tumor promoter and a tumor suppressor highlights a potential need for 
transient repression of E-cadherin expression in the progression of prostate 
cancer. The PI3K/AKT signaling pathway is one pathway that can mediate this 
transient repression of E-cadherin expression in prostate cancer as the functional 
analysis performed in this study demonstrated that the activation of AKT leads to 
a significant reduction of E-cadherin expression. Interestingly, neither the loss of 
E-cadherin based adherens junctions nor the activation of AKT affected the 
expression of DSG2, suggesting that the observed loss of E-cadherin and DSG2 
expression in primary prostate cancer may be regulated by separate 
mechanisms. In conclusion, this study has provided an in depth analysis of the 




expression by the PI3K/AKT signaling pathway in prostate cancer, and has 
demonstrated the potential utility of E-cadherin and DSG2 as markers of 
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